Unraveling the Single-Cell Spatial Landscapes of Melanoma Brain Metastases

Artür Manukyan[1,*,§], Kristin Peters[2,*], Helena Radbruch[3], Florian Rossner[4], Annika Lehmann[4], Karsten Kleo[4], Thomas Conrad[5,6], Janine Altmüller[5,6], Izabela Plumbom[5,6], Altuna Akalin[1], Karsten Jürchott[7], Emanuel Wyler[1], Markus Landthaler[1,8], Josefine Radke[2,9,#,§], Torben Redmer[9,10,#,§]

[1]Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology, Berlin, Germany

[2]Institute of Pathology, University Medicine Greifswald, Greifswald, Germany

[3]Institute of Neuropathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

[4]Institute of Pathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

[5]Genomics Technology Platform, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

[6]Core Facility Genomics, Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany

[7]Berlin Institute of Health (BIH) Center of Immunomics, Charité – Universitätsmedizin Berlin, Berlin, Germany

[8]Institut für Biologie, Humboldt-Universität zu Berlin, Berlin, Germany

[9]Institute of Molecular Genomics and Core Unit Genomics (CUG), University Medicine Greifswald, Greifswald, Germany

[10]Institute of Pathology, Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Austria

*These authors contributed equally as first authors

#These authors contributed equally as senior/last authors

28 §Corresponding authors: artur.manukyan@mdc-berlin.de, josefine.radke@med.uni-
29 greifswald.de, torben.redmer@med.uni-greifswald.de

Summary

The cellular composition that defines the tumor ecosystem plays a crucial role in determining

the responsiveness of tumors to immune checkpoint inhibitors (ICi) and pharmacological

blockade of BRAF (BRAFi). However, the compositional changes that likely shape the

ecosystems of primary melanomas for metastasis to the brain on the one hand and the

progression of brain metastases on the other remain unclear.

In this study, we resolved the spatial landscapes of progressive melanoma brain metastases

(MBM) by profiling 13 regions from 8 distinct metastases, together with one matched primary

tumor spanning various stages of tumor development and therapeutic intervention. Single

cell resolved spatial transcriptomics-based profiling uncovered distinct and common patterns

of MBM progression. Our approach revealed remarkable cellular and spatial heterogeneity

and identified key tumor subsets of MET or NGFR expressing cell populations. Moreover,

spatial profiling of tumors which have progressed under ICi or BRAFi identified BZW2$^+$ tumor

cells contributing to an immune-suppressive microenvironment, preventing immune cell

infiltration and dispersion within the tumor. Elevated BZW2 expression was associated with

resistance to ICi therapy and is inversely correlated with the antigen transporter TAP1.

Spatially-aware automated profiling of immune cell-enriched areas revealed "hot" niches

characterized by tumor cell expression of TAP1, PD-L2, HLA-DRA whereas "cold" niches

featured high levels of particularly BZW2 and SOX4. The latter suppressor of translation and

transcriptional regulator was co-localized with the clinically targetable MET receptor in a

subset of tumor cells that exhibit immune evasion features. In summary, we provide for the

first time, spatially resolved landscapes of MBM that reveal insights into the cellular

heterogeneity of tumors and the mechanisms underlying immune escape.

Keywords

56   Spatial biology, brain metastases, melanoma, immune suppressive programs

Introduction

Tumor development and progression are highly dynamic processes[1] that are temporally

defined and driven by a complex interplay of genetic aberrations[2], environmental factors, and

spatial mechanisms which in turn are regulated by communication with the tumor

microenvironment (TME). While the genetic landscape of tumors provides a fundamental

blueprint for their progression[3], the emergence of subclonal populations[4] and the crosstalk

between tumor and stromal cells particularly involving soluble factors and extracellular

vesicles[5] play crucial roles in shaping the heterogeneity and therapeutic resistance observed

in cancer. The development of brain metastases is observed in 40–60% of melanoma

patients during the course of the disease and, as in patients with lung and breast cancer[6] is a

major contributor to disease progression and poor prognosis of patients[7-9]. In the context of

brain metastases, astrocytes, oligodendrocytes and tumor-associated macrophages (TAMs)

are the most important tumor cell interactors and contribute to the establishment of distinct

tumor niches in the brain[10]. These in turn facilitate the maintenance and progression of

metastatic tumor cells, hence determining the course and routes of development from initially

small and asymptomatic brain micrometastases to symptomatic macrometastases[10] through

intricate signaling networks[11].

Currently, therapeutic targeting of the PD-1/PD-L1 axis or LAG-3 interactions with

neutralizing antibodies represents one of the most important strategies for restoring T cell

activation and enabling tumor cell recognition and elimination[12]. Despite a subset of patients

showing complete intracranial response (CR) to ICi, immune resistance programs (IRPs)

evolve in the majority of patients and hence determine the clinical response of MBM to anti-

PD-1 therapy[13,14]. Likely, environmental stresses induced by BRAFi targeting the mutated

and hyperactivated BRAF kinase ($BRAF^{V600E/K/R}$) or ICi both aiming to block tumor growth can

also remodel the TME and alter the dynamics of tumor-stromal interactions[15]. These

observations highlight the complexity of the TME and underscore the limitations of current

therapies in overcoming the tumor's ability to evade the immune system and develop therapy

resistance.

Previous studies identified gene signatures predicting the response of melanoma to ICi[13,16,17],

among them a tumor-intrinsic NGFR (nerve growth factor receptor)-associated gene

signature predicting anti-PD-1 therapy resistance[18]. However, signature genes likely reflect

multiple concerted molecular mechanisms of immune cell (T cell) suppression, involving

potentially interacting tumor and stroma cell-associated mechanisms. The insufficient

immune cell infiltration into MBM remains a major barrier to effective therapy.

Epithelial-like MBM, characterized by expression of Ecad (CDH1), adopt an NGFR$^+$ cell

phenotype in response to antigen-specific cytotoxic T cells[18] or therapeutic

interventions[19].Hence, only a minority typically early-stage or therapy-naïve tumors might

exhibit high levels of immune cell infiltration[20]. Therefore, ICi therapy might be ineffective in

MBM featuring low levels of tumor immune cell infiltration and IFNγ scores[20] besides low PD-

L1 expression[21]. The efficacy of immune checkpoint inhibitor (ICi) therapy is likely influenced

by additional, predominantly spatially regulated mechanisms, such as the presentation of

tumor antigens to adjacent immune cells[22]. Moreover, the different developmental stages and

molecular phenotypes of MBM, likely determine the response to therapeutic interventions

and the transition from a tumor growth suppressive to an inflammatory and progressively

evolving microenvironment that promotes tumor growth and metastasis[23].

Brain metastases likely consist of spatial areas with varying levels of sensitivity and

resistance to therapy, posing a major challenge to the development of more effective

treatments. To address these challenges, we have employed spatial transcriptomic profiling

to investigate the molecular landscapes of MBM (n=16) including whole sections of matched

primary and brain metastasis (total n=2) and primary and relapsed MBM (total n=2).

Moreover, we investigated the methylome-based copy number variation (CNV) profiles of

progressive tumors (n=4). Here, we present single cell and spatially resolved landscapes of

MBM of diverse therapeutic and developmental stages.

Results

BZW2 and TAP1 discriminate immunologic niches in MBM

Immune checkpoint inhibitors (ICi) achieved durable responses and improved survival in

advanced-stage melanoma patients[24]. However, only small and asymptomatic brain

metastases were susceptible to disease control[14,25]. The formation of spatially defined

immunosuppressive areas probably accompanies tumor development and intrinsically

determines ICi-resistant areas within larger tumors.

We evaluated the representation of immune suppressive programs which potentially

mediated resistance of MBM to ICi therapy. To this end, we surveyed bulk expression data of

MBM and brain control samples (BC) of our previous study[19]. A pan-MBM gene signature

was revealed by comparing MBM with BC samples from non-cancer autopsies to subtract

genes only expressed in adjacent CNS tissue. Comparison of previously identified IRP and

pan-MBM signature genes[13] revealed 59 MBM expressed IRP genes (Figure S1a, Table S1).

Gene set enrichment analysis (GSEA) illustrated the extent of enrichment of potential

suppressors and activator of immune response in MBM, hence representing the "on-off"

status of immune resistance. As expected, GSEA revealed enrichment of genes of both

molecular programs (Figure S1b). We identified the regulators of translation and transcription

BZW2[26] and SOX4[27] serving as potential mediators of IRP in MBM. BZW2 and SOX4 were

predominantly expressed in MBM and MBM-derived cell lines (BMCs), but not in BC samples

(Figure S1c), similar to the recently identified immune suppressor CDK4. A survey of

scRNAseq data of ICi responsive and refractory melanoma (GSE115978)[13] revealed

increased levels of BZW2 and SOX4 in post-treatment tumors (Figures 2a, 2b and S1d), with

no obvious relation to PD-L1 expression (Figure S1e). The correlation of ICi-related disease

progression stages with the tumor´s expression profile provides insights into response-

determining mechanisms. We observed increased levels of BZW2 and SOX4 in post-ICi
melanoma featuring high immune resistance (Figure 2b,c). In contrast, we observed a
significant reduction in the levels of the peptide transporter TAP1 which mediates the
translocation of peptide antigens for loading onto MHC class I molecules such as HLA-A
(Figure S1f)[28]. In concordance, melanoma patients with tumors expressing high levels of
BZW2 (HR=1.55, logrank P=0.0011) and SOX4 (HR=1.52, logrank P=0.0019) showed
unfavorable overall survival (OS, TCGA-SKCM, n=459). TAP1 expression on the other hand
was associated with favorable OS (HR=0.45, logrank P=4.4×10^{-6}) (Figure S1g).

Tumor ecosystems can change over time, either evolving phenotypes that are intrinsically
resistant to ICi therapy or developing immune resistance in response to ICi therapy. We
applied spatial transcriptomics using the Xenium in situ profiler (10X Genomics) to
investigate the spatial composition of individual cells in ICi-resistant or cross-resistant "cold"
areas and in ICi-sensitive and potentially "hot" niches by profiling 13 regions from 8 distinct
metastases, together with one matched primary tumor spanning various stages of tumor
development and therapeutic intervention. We annotated single cells by performing
downstream unbiased clustering analysis of Xenium single cell RNA profiles, followed by the
automated alignment of post-Xenium H&E images.

We first investigated an NRAS (NRAS^{Q61L})-mutated primary mucosal melanoma (mM) that
was first diagnosed in the nasal cavity in 2021. The tumor showed progression to the
frontotemporal lobe of the brain under ICi therapy and was resected 4 months after ICi was
terminated (Figure 2d, Figure S2a). The spatial mapping of the primary mM and of the
concordant mMBM allowed analysis of ~410,000 cells and ~290,000 cells respectively and
revealed landscapes comprising up to 12 different tumor cell subtypes (TCs), infiltrated
tumor-associated macrophages/microglia (TAMs), immune cells, proliferating/cell cycle
progressing cells, vascular-leptomeningeal cells and cancer-associated fibroblasts
(VLMC/CAFs) as well as adjacent epithelial cells (CDH1/Ecad$^+$, CXCL14$^+$) of the primary mM
and MBM-associated astrocytes (GFAP$^+$), (Figures S2b, c). Additionally, we identified a rare

SLC17A6$^+$ (glutamate transporter) cellular subset of uncertain prognostic relevance which

was unique to the primary tumor but depleted in the MBM. Moreover, we observed well-

defined and spatially separated areas of enrichment or depletion of immune cells. Immune

cells were predominantly enriched at sites of high tumor cell expression of TAP1 (Figure 2e

and Figure S2b, c; TCs_4, Table S2). By contrast, high BZW2 expression was observed in

tumor cells located in immune cell-depleted areas (Figure 2e and Figure S2b, c; TCs_7,

TCs_8, Table S2). Identifying the top-expressed genes characteristic of each cell type cluster

enabled accurate classification and a better understanding of the cell types. Immune

suppressive BZW2$^+$ cells showed cellular heterogeneity and accompanied co-expression of

SOX4 and BCAN or CD93 (TCs_7, TC_8; Table S2; Pat 90 primary mM) and TAP1$^+$ tumor

cells co-expressed STAT1 among additional markers (Figure S2c, Supplementary table 2;

Pat 90 primary mM). Furthermore, we observed that the proportions of the major cell types

reflected changes in cellular composition that likely occurred during the progression of brain

metastases (Figure S2d, left panel).

Spatial profiling enabled the characterization of immunogenic niches

Based on the results obtained so far, we hypothesized that TAP1 and BZW2 play

antagonistic roles in regulating immune cell infiltration. Therefore, we examined the changes

in cellular composition associated with the spread of tumor cells into the brain, focusing on

the persistence of immune suppressive BZW2$^+$ and immune supportive TAP1$^+$ areas in the

resulting mMBM.

The comparative spatial mapping revealed loss of immune suppressive BZW2 areas but

maintenance or emergence of TAP1$^+$ areas in the brain metastasis (Figures 2g and S2d,

right panel). In addition to the spatial mapping of individual genes, we sought to investigate

the spatial distribution of areas with a high abundance of immune cells, represented by the

immune score (IS). The IS was calculated in two ways, using the ESTIMATE signature,

which includes predefined genes associated with immune cell infiltration and activation[29]. IS

determined from pseudo-bulk data using single-sample gene set enrichment analysis

(ssGSEA) provided insights into the total immune cell content, but only spatial mapping of

values assessed using the AddModuleScore function from Seurat (Table S3) revealed

immunogenic niches, even in tumors with low total IS.

Consistent with the loss of BZW2$^+$ cells, we observed that IS^{high} areas largely coincided with

TAP1 expression (Figure 2h). Furthermore, we observed mutual exclusivity of TAP1

expression and lowest immune scores within BZW2$^+$ tumor cell-enriched niches (Figures 2g,

h).

We have performed hot spot analysis using VoltRon[30] toolbox to detect local

microenvironments with IS^{high} cells (see Methods). Here, the method automatically labels

each cell as "hot" if the Getis-Ord test[31] is found significant for that gene, indicating that the

cell is within proximity to a region abundant with IS^{high} cells, and labelled as "cold" otherwise.

Considering the various stages of development, it is likely that immunogenic ("hot") and

suppressive ("cold") niches evolve and deplete over time and along progression which was

evident by automatically niche mapping (Figure 2i, left panels and Figure S3), hence

determining the tumor landscapes and therapy responses. We observed that TAP1$^+$ tumor

cells were the main contributors of immunogenic niches, however only a subset of niche-

supportive tumor cells were maintained during brain metastasis or in the establishment of the

brain tumor (Figure 2i, right panels and Figure S3). Moreover, we found general (other)

markers which not significantly classified niches. In order to identify valid markers that

characterize cold and hot niches independently of the tumor's mutation and therapeutic

status, we performed differential expression (DE) analysis (see Methods) of the previously

defined TAP1$^+$ tumor cell niches surrounding IS clusters (group of cells with high IS).

Differential expression analyses of tumor cells alone or of tumor cells and environmental

cells (TME) of aggregated niches across TMA samples and whole tumors validated TAP1,

HLA-DRA, PD-L2 (PDCD1LG2) and ITGB2 as major contributors of immunogenic niches

(Figure 2j, upper row). In contrast, BZW2, PSENEN, SOX4 and SOX6 served as main

mediators of an immune suppressive environment (Figure 2j, upper lower row). In addition to

single genes, we applied state-predictive gene signatures for calculation of scores (Table S5)

and observed significant enrichment of immune-related molecular programs, particularly

ESTIMATE, Roh, IPRES (innate PD-1 inhibitor resistance[32]) and NRS (Neoadjuvant

Response Signature[17]) in "hot" niches. In addition to immune cells, we observed a significant

enrichment of TAMs expressing C1QC, TMIGD3 and AIF1 in immune "hot" niches. The

comprehensive niche profiling uncovered differential niche-dependent regulation of

additional, immune cell-specifying signatures and revealed NGFR-related programs

unrelated to BZW2$^+$/SOX4$^+$-associated immune suppressive niches (Table S5). In line with

our data, we suggest that immunogenic niches comprise an immune cell and TAM enriched

core which is surrounded by TAP1$^+$ tumor cells embedded into the BZW2$^+$ suppressive

environment (Figure 2k, upper scheme). The model is supported by the distance of TAP1$^+$

and BZW2$^+$ tumor cells to the nearest immune cell as defined by expression of a gene

signature which includes markers such as CD3G, CD8A, CD4, TRAC and PTPRC among

others. Proximity calculation across all niches revealed an average distance of 4.2($\pm$0.9) μm

and 5.8($\pm$1.0) μm of TAP1$^+$ cells (n=61,071) and BZW2$^+$ cells (n=146,947) to the nearest

immune cell (Figures 2k, lower scheme and 2l; Table S6), respectively.

Despite the robust separation of these niches, TAP1 and the MHC class II molecule HLA-

DRA are expressed by both tumor cells and immune cells, including activated T cells[33,34].

Along with other markers, this expression facilitates the immune response[35]. Tumor cell-

expressed TAP1 is essential for the presentation of tumor antigens enabling recognition by

immune cells. Therefore, TAP1 deficiency is associated with a lack of cytotoxic CD8$^+$ T

cells[36]. Consequently, the down regulation of TAP1 in tumor cells serves as an important

mechanism of immune evasion[37]. On the other hand, the absence of TAP1 expression in T

cells severely impairs antigen presentation, particularly the presentation of cytosolic antigens

to class I-restricted cytotoxic T cells results in reduced surface expression of MHC class I

molecules and an absence of mature CD8[+] T cells[36,38]. Within the immune cell cluster, we

identified putatively activated cytotoxic T cells characterized by the expression of TRAC and

HLA-DRA, in addition to TAP1 and CD8A (Figure 2m, right panel).

Spatial mapping of the cellular subgroups of the primary mM and the corresponding

metachronously developed mMBM provided insights into the changes in the cellular

composition of the tumors that were likely associated with metastatic progression. We

observed that TAP1 and BZW2 expressing "hot" and "cold" niches were maintained or re-

established during mMBM formation and progression. Moreover, we observed a minor cell

population exhibiting high expression of BZW2, low TAP1 expression and depletion of

TRAC[+] T cells (Figure 2n). Generally, levels of BZW2 and SOX4 were reduced in MBM

(Figure S2e). In concordance with reduced expression of immune suppressive molecules, we

observed higher immune scores and enrichment of CD8A[+] T cells in MBM (Figure S4a). To

assess the extent of global changes that may occur during metastatic progression we

performed methylome-based copy number variation analysis using the EPICv2 (930k)

technology. We observed amplification of several genes on chromosome 7, including the

MET receptor (Figure S4b). FISH (fluorescence in-situ hybridization) analysis validated the

amplification of MET and of chromosome 7 (CET7) in mMBM (Figure S4c, Table S7).

In summary, the comparative spatial profiling of matched primary mM and MBM revealed

that BZW2 and TAP1 define distinct areas which potentially support or suppress immune cell

infiltration and activation. Despite the changes in tumor ecosystems occurring alongside

brain metastatic progression of the primary tumor, immune cell suppressive and supportive

niches were restored in the MBM. The BZW2[+]/TAP1[low] cells may be prone to metastasize to

the brain.

The presence of immune niches is associated with an active interferon response

Our previous results suggest that BZW2 and TAP1 serve as markers distinguishing

immunogenic niches in melanoma (Figure 3a), however not excluding intermediate states

showing co-expression of both determinants of immune surveillance. In order to assess the

relevance of these genes and tumor states, we investigated survival probabilities of

melanoma patients featuring distinct high or low or co-expression of TAP1 and BZW2. We

indeed observed the highest survival probability of patients (TCGA-SKCM, n=459) featuring

BZW2^{low}/TAP1^{high} expression and lowest survival probability of BZW2^{high}/TAP1^{low} patients

(Figure 3b). This suggests that the presence of TAP1 serves as an indicator of favorable

prognosis depending on the level of BZW2. Therefore, TAP1 and BZW2 could serve as novel

prognostic biomarkers for the survival of melanoma patients.

The separation of patient groups was even more evident with regards to the levels of HLA-

DRA. Patients with high levels of HLA-DRA exhibited the most favorable prognosis; however,

co-expression of BZW2 attenuated this beneficial effect (Figure S5a). In concordance to our

previous observation, TAP1 expression served as a potential prognostic marker suggesting a

higher survival probability of melanoma patients with TAP1^{high} MBM (Figure S5b). Next, we

thought of identifying genes that may define the molecular states of BZW2^{+} or TAP1^{+} cells.

To unravel the potential global networks associated with BZW2 and TAP1, we determined

the differentially expressed genes of TAP1$^{high/low}$ and BZW2$^{high/low}$ tumor cells (malignant cells)

from whole transcriptome gene expression of treatment-naive MBM (GSE200218) (Figure 3c

and Figure S5c). TAP1^{high} cells showed co-expression of interferon (IFN)-associated genes

such as IFI6. In contrast, BZW2^{high} cells were particularly enriched for CHL1 (Cell Adhesion

Molecule L1 Like) and CTNNA2 (Catenin Alpha 2) (Figure 3d, Table S8). Suggesting a

correlation of niches of TAP1^{+} cells and interferon signaling, we found the downstream

mediator of IFNα/β signaling MX1 and the target of IFNγ signaling LGALS9 significantly

higher expressed in "hot" spatial niches (Figure 3e) and showed a moderate correlation

(Figure 3f, left panel). In order to establish a role of IFN signaling (Figure 3f, right panel) for

the possible emergence and maintenance of immune cell-enriched niches, we spatially

mapped the expression of IFI6 (Interferon Alpha Inducible Protein 6) on primary mucosal

melanoma (Figure 3g, left panel).

The mapping of major cell types to discrete IFI6^{high} areas revealed an immune (T) cell niche

in the primary tumor which was embedded into a well-organized microenvironment of tumor

cell subsets (TCs_3, TCs_7, Table S2) and interferon expressing tumor cells (Figure 3g,

second left panel). The analysis of tumor cell types revealed co-occurrence of TRAC$^+$ T cells

and interferons MX1 and IFI6 and showed a clear separation of BZW2$^+$ and TAP1$^+$ niche

cells and a potential key role of the IFN signaling pathway (Figure 3g, right and second

right)[39]. Considering the complex process of metastasis and the unique environment of the

brain[40], we investigated the mediators of interferon signaling in the brain metastatic

(Secondary immune niche) immunogenic niche. Albeit less abundant, we observed hot spots

of IFI6 expression in the mMBM (Figure 3h, left panel). The cell type analysis of the

secondary immune niche uncovered a tumor subtype-specific enrichment of immune (T) cells

(Figure 3h, second left panel). The classification of cellular subtypes demonstrated the

mutual exclusivity of expression of interferons and BZW2 and showed once more the

association of TAP1$^+$ and enrichment of TRAC$^+$ cells in TAP1$^+$/MX1 or TAP1$^+$/IFI6$^+$ areas

(Figure 3h, right panels). The loss of TAP1 expression in tumor cells may be the

consequence of genetic aberrations or defects in inducing signaling pathways such as IFN

signaling[41,42]. The signal transducer and activator of transcription 1 (STAT1) and STAT2

serve as key factors of interferon signaling[39]. This suggests a lack of STAT1 expression in

immune-repressive or "cold" BZW2$^+$ tumor cells, with BZW2^{high}/STAT1^{low} melanoma patients

exhibiting the lowest overall survival (Figure S5d).

We found STAT1 spatially co-expressed particularly at TAP1^{high} sites of primary mM and

mMBM (Figure 3i left panel, Figure S5e, Table S2) and associated with enrichment of T cells

(TRAC$^+$) (Figure S5f). In contrast to STAT1, we observed overlapping rather than mutually

exclusive patterns of spatially expressed SOX4 and MET and to a lesser extent, PSENEN

(Figures S5g, h). MET was co-localized with BZW2 at restricted areas within the mMBM

(Figure S6a). Immunohistochemistry validated STAT1 and HLA-DR(A) expression at TAP1[+]

areas and showed sites of low or absent expression of both markers of immune supportive

areas (Figure 3i, center panels and Figure S6b). Here, we provide evidence that BZW2 not

only shows mutually exclusivity with TAP1 but demonstrated that low STAT1, MX1 and IFI6

levels were associated with high BZW2 expression, suggesting that BZW2 may be

associated with suppression of STAT1-mediated signaling, which in turn drives TAP1

expression. In line we observed that TAP1 and STAT1 showed association with a

comprehensive immune-associated protein interaction-network among them the immune

proteasomes PSMB8/9, major histocompatibility complex class I genes and interferon-

inducible genes e.g. IFI6 (Figure S6c).

BZW2/TAP1-associated programs function across MBM of different therapeutic stages

Therapeutic interventions likely foster selection of cellular subsets featuring minimal residual

disease (MRD)[43,44], suggesting that MBM which have been developed under therapy may

comprise drug resistant, stem-like cells. We performed a thorough analysis of TMA samples

for identification of the spatial single cell heterogeneity of MBM across different patients who

received BRAFi and/or ICi therapy (Figures 4a upper scheme, S7a, Table S3) and to

investigate the distribution and occurrence of BZW2 and TAP1 in niches across multiple

progression stages. Unbiased clustering of Xenium cells followed by automated H&E image

alignment (see Methods) revealed distinct and common proportions of cellular sub clusters

regarding the molecular phenotypes (e.g. Ecad[+], NGFR[+], MET/SOX4[+]) and separation of

tumor cells from CNS tissue and from primary CNS lymphoma (PCNSL) (Figures 4a lower

panel and 4b, S7b-c). Despite the different origins and developmental strategies of MBM and

PCNSL both malignancies likely accompany restructuring of the brain environment. The

comparison enables us to disentangle tumor-intrinsic factors from microenvironmental cues

driving tumor progression and immune evasion.

Tumor specimen revealed pronounced intertumor and intratumor heterogeneity showing

distinct and overlapping expression of markers specifying different tumor cell clusters,

immune cells, TAMs, endothelial cells and CAFs (Table S2). Marker analysis of clusters and

joint interactive visualization of cells via H&E images enabled the annotation of tumor cell

subtypes (TCs, cycling TCs, NGFR[+]) and non-tumor subtypes (immune cells, TAMs,

VLMC/CAFs, endothelial cells) and CNS-derived cells (astrocytes, oligodendrocytes,

neurons) across tumor specimen and uncovered the molecular features of general cycling

(MKI67/TOP2A/PCNA) and non-cycling tumor cells of NGFR[+] subsets (Figure 4b, c).

Astrocytes and oligodendrocytes presented the major cell types of the TME.

Oligodendrocytes were most prevalent in tumor-adjacent central nervous system (CNS)

tissue, neurons were found at distant tumor sites or in association with micrometastases (Pat

24). Immunohistochemistry (IHC) further revealed the sub-classification of NGFR[+]/de-

differentiated/amelanotic and Ecad/melanocytic (MLANA[+]/ HMB45[+]) tumors (Figures S8a-b

and 9a-b) and characterized the degree of immune /CD3[+] T) cell infiltration, highlighting the

spatial distribution of "hot" and "cold" niches (Figure S10a). All TMA tumor specimen showed

infiltration of Iba1[+] TAMs (Figure S11a).

We evaluated the TMA specimens using the immune score (IS), which indicates the degree

of immune cell infiltration as calculated from pseudo-bulk expression data, and spatially

mapped the expressions of BZW2, SOX4 and NGFR (IS, Table S3, Figure 4d). We observed

that TMA specimen featuring high homogeneously expressed NGFR (Pat23C) or BZW2 and

SOX4 (primary mucosal melanoma, Pat90-P and Pat23C) showed lowest IS. However, bulk

data-derived scores only inadequately reflected the immunogenic status of tumors. The

UMAP representation of deconvoluted TMA samples revealed highest levels of IS in immune

cells and revealed an opposite expression pattern of BZW2 and TAP1 (Figure 4e) with no

apparent correlation to therapeutic treatment strategies, but rather to molecular patterns

(Figure S12a-b). Moreover, cellular clusters of HLA-DRA and MET/SOX4 defined TAP1[+] or

BZW2[+] areas (Figures S12c-d). De-differentiation may be driven by the concerted action of

BZW2/SOX4 and/or NGFR and several lines of evidence suggest an immune suppressive

role of NGFR[18,45]. However, the results of our niche profiling suggested that NGFR

expression may not directly contribute to BZW2- or SOX4-associated "cold" niches. We

investigated the spatial environment of an IS^high/TAP1+ immune hot spot within the NGFR+

tumor (Pat23) on single cell level (Figure 4f, left panels). We observed that the "hot" niche

consisted of TAP1+/IFN+/BZW2^low cells and showed enrichment of particular IFI6 (Figure

S12f). In line with previous observations, we suggest that established immunogenic niches

employ interferon signaling to maintain T cell subsets (Figures S12f, g)[46]. For a deeper

analysis of the immune hot spot, we investigated the pattern of co-occurrence and transcript

density across the cells which made up the niche. Niche-forming tumor cells showed high

levels of TAP1 and HLA-DRA transcripts and low levels of BZW2 (Figure 4f, Figure S12f, g),

which is probably ideal for the recognition of tumor antigens[47] by attracted and activated

CD8A+ T cells which in turn exhibited only low expression of the checkpoint markers CTLA4

and PD1 (Figures 4g-h, S13a).

In summary, spatial profiling of TMA samples confirmed the existence of immune

suppressive and supportive programs associated with BZW2 and TAP1 across tumors of

different therapy stages demonstrating high concordance with matched whole tumor sections

which revealed high robustness in terms of the composition of niches.

Spatial profiling of MBM-adjacent CNS tissue revealed different states of inflammation

The mutual interactions of brain infiltrating tumor cells with neighboring cells, particularly

astrocytes, microglia/TAMs and oligodendrocytes trigger inflammatory processes[48,49]. Recent

studies in glioblastoma demonstrated that tumor-adjacent astrocytes cause an anti-

inflammatory environment suppressing T cell activation[50]. The reactive states of tumor

environmental cells, particularly astrocyte activation have been intensively studied in mouse

models[51] and in the context of neurodegenerative diseases[51,52], however have not been

studied in MBM in a spatial context. Therefore, we investigated MBM-adjacent CNS tissue for levels of AIF1/Iba1 and GFAP, well-recognized markers of activation of TAMs and astrocytes by IHC. We observed strong reactivity of TAMs at tumor distant and adjacent areas and activation of only tumor-adjacent astrocytes (Figure S14a, b). Spatial profiling revealed a main fraction of GFAP$^+$ astrocytes with at least three different subsets. Most tumor-proximal astrocytes exhibited a reactive/"A1" or neuroinflammatory phenotype (GFAP$^+$/ CHI3L1$^+$/SPP1$^+$)[53,54], whereas more distal astrocytes (GFAP$^+$/GJA1$^+$/AQP4$^+$) appeared to adopt a homeostatic[47] rather than reactive[48] state (Figure S14c-f). In contrast to adjacent astrocytes and TAMs, we observed neurons (SNAP25$^+$/SYT1$^+$) nearly exclusively at distant sites and might not or at early stages primarily engage with tumor cells in MBM (Figure S14g, h).

Our survey suggests that reactive astrocyte subsets probably emerge only in response to physical interaction with tumor cells and might contribute to suppression of T cell activation.

Spatial profiling uncovered molecular programs of de-differentiation

Genetic factors and environmental cues determine the routes of tumor development and progression. Our latest results suggest that tumors comprise therapy-responsive and refractory areas both reflecting certain cellular compositions. To further unravel the cellular subsets which may support or suppress immune cell infiltration we investigated a punch of the primary mucosal melanoma-derived MBM (Pat90) which emerged over the course of four months of nivolumab/ipilimumab therapy and exhibited an extremely diverse landscape. We identified MET$^+$ cellular subsets featuring co-expression with Ecad, ABCB5, SOX4, BZW2 or TAP1 and median expression of PD-L1$^+$ (Figure S15a-d). As previously established immune cells nearly exclusively located to TAP1$^+$ areas (Figure S15c, d).

On the molecular and single cell level, SOX4 expression clearly discriminated MET$^+$ subsets (Figures S15e, f). MET activation (Figure S15e) likely provides growth and cell survival

benefits to tumor cells. We observed that melanoma patients with low levels of MET, SOX4 and BZW2 showed most favorable outcome while the combination of MET[high]/BZW2[high], MET[high]/SOX4[high] and BZW2[high]/SOX4[high] was associated with worst survival probability (Figures S15h-j).

The de-differentiation of melanoma is linked with stemness and expression of NGFR[18,55], however the cellular features of de-differentiated NGFR[+] tumor cell states, suggesting that NGFR served as yet another not well characterized layer of immune suppression. In contrast to the Pat15 specimen, which featured immune cell infiltration despite expression of NGFR, the tumors showed Ecad[+] areas, i.e. a rather differentiated than de-differentiated phenotype. The latter phenotype was particularly evident in Pat 23 specimen, associated with high expression of NGFR. We observed up to ten tumor cell subsets showing overlapping single cell spatial pattern and validated the co-existence of proliferating/cycling (TOP2A[+]) and dormant/non-cycling populations of NGFR[+] cells, suggesting distinct therapeutic responses of the cellular subsets. We observed that the cluster of NGFR[+] cells was characterized by additionally featured expression of LIFR (leukemia inhibitory factor receptor), LOX (lysyl-oxygenase), AXL (AXL receptor tyrosine kinase) and TRIL which we found associated with NGFR in our previous study[19] (Figure S16a-d). The more detailed marker analysis of sub clusters revealed additional characteristics of NGFR[+] cells such as association with SRY-box transcription factors such as SOX4[56], SOX9[57] and SOX11[58] (Figure S16e), transcription factors that are known to promote dedifferentiation.

The expression of NGFR in melanoma has been associated with stemness, cell migration, drug resistance and immune suppression. However, the progressive phenotype of NGFR[+] cells and patients' outcome seem to be highly dependent on the effects of associated and co-expressed genes. While the exact mechanisms of activation of NGFR in solid cancers, particularly melanoma, remains elusive, several lines of evidence suggest a connection between APP (Amyloid Beta Precursor Protein) and NGFR activation mediated NGF (Nerve Growth Factor). We observed APP expression in close proximity to NGFR-positive cells in a

subset of tumors (Figure S16f). NGFR expression was associated with poorer survival,

particularly in tumors with co-expression of APP or SOX4 (Figure S16g-i). Most intriguingly,

we found distinct and co-expression of NGFR and AXL showing different levels of patient

outcomes. Our spatial transcriptomics approach validated most genes of the previously

identified NGFR signature and revealed heterogeneity of NGFR$^+$ subgroups that could define

distinct routes of tumor progression.

Signature genes spatially separate MBM into areas of immune response and

resistance.

The profiling of immunogenic and suppressive niches revealed differentially regulated genes

that likely classify distinct molecular programs of immune suppression and activation. We

examined a dedifferentiated (NGFR$^+$), NRAS^{Q61R}-mutated MBM (Pat 15) that progressed

under ICi therapy and showed extensive areas of BZW2 expression and T-cell hotspots

(CD3$^+$) (Figure 5a) featuring high immune scores (Figure 5b). Punch from the specified areas

of the tumor showed remarkable cellular heterogeneity and an accumulation of potentially

immunosuppressive tumor cells (Figure 5c) which expressed BZW2/SOX6, NGFR or

MET/SOX4. We defined 30 of the most significantly differentially regulated genes between

niche-forming tumor and environmental cells from hot and cold niches (Table S10) as

markers for spatial immune resistance or activation programs (SIRP, SIAP). The mapping of

SIRP and SIAP scores spatially separated tumors into immune cell enriched and depleted

areas and suggested a switch in immune programs during brain metastatic progression and

different responses of primary and brain metastatic tumors to ICi therapy. (Figures 5d, e).

Moreover, SIRP and SIAP showed concordance with gene signatures indicating immune

activation and favorable outcome (Figure 5f) as revealed by single sample GSEA (ssGSEA).

A more detailed analysis of TAP1 or BZW2 protein levels showed a close proximity of TAP1$^+$

tumor cells and CD3$^+$ T cells (Figure 5g, left column) and low BZW2 expression in T-cell-

adjacent tumor cells. In line, we observed marginal distribution of T cells within BZW2$^+$

zones, further supporting the different characteristics of tumor cells with high or low BZW2

expression. Next, we assessed the association of SIRP and SIAP with clinical outcomes.

Single sample GSEA of MBM (n=79, study EGAS00001003672) validated SIAP and

favorable outcome-predicting signature genes indicating the level of macrophages or

responses to ICi therapy (neoadjuvant response to anti-PD1 therapy; NRS, Nivolumab

response, IMPRES) or T-effector-interferon-γ-associated gene expression enriched in MBM

with high levels of tumor-infiltrating lymphocytes (TIL) (Figure 5h). SIRP signature was

inversely correlated and predominantly expressed in TIL^{low} tumors (p=0.044).

Given that loss of TAP1 expression serves as an important mechanism of immune resistance

in melanoma[36,39], a loss of TAP1 was observed in 28.6% (4/14 patients, study GSE115978)

(Figure 5i,j), suggesting that the downregulation of TAP1 serves as an immune escape

mechanism in a subset of tumors, possibly in conjunction with an increase in BZW2. We

suggest that SIRP and SIAP may serve as indicators of response to ICi. Accordingly, levels

of CDK1 or LGALS3, STAT1, and IFI6 were increased or decreased after ICi therapy (Figure

5k) and distinguished, albeit only tentatively, between disease stages in melanoma patients

(Figure 5l). To assess whether SIRP and SIAP distinguish melanoma patients suffering from

progressive disease (PD) or show complete (CR) or partial response (PR) to ICi therapy

(study GSE91061), we performed ssGSEA. We observed overlapping and distinct patterns of

expression of SIRP and SIAP, however both programs significantly distinguished patients

with PD or PR/CR (Figure 5m, n). We found PTPRZ1 or TRAC, CD8A and the NRS

signature associated with SIRP or SIAP, respectively (Figure 5o).

In addition to melanoma, we assessed whether BZW2 and TAP1 might determine the

survival of breast cancer patients. BZW2 was higher expressed in breast cancer brain

metastases (BCBM) which showed lower SIAP expression than the primary tumors (Figures

5p, q left panel). In line with previous observations in melanoma and MBM, TAP1 expression

was associated with favored survival only in the absence of BZW2 expression and worst

outcome in patients with high BZW2 levels (Figure 5q, right panel).

Spatial profiling revealed different ecosystems of patient-matched MBMs from different regions of the brain.

The development of multiple brain metastases presents a frequent therapeutic challenge in melanoma and lung cancer patients. Although gammy-knife radiation therapy and MAPKi or ICi therapy shows efficacy, the heterogenic response of the multiple tumors drives disease progression. The reactivation of the MAPK pathway in BRAFi therapy resistant tumors confers cross-resistance to ICi[55], hence establishing an immune-evasive tumor microenvironment. To decipher the ecosystems of two matching brain metastases that occurred in the cerebellum and frontal lobe of a patient with cancer of unknown primary (CUP) (Figure 6a), we performed spatial profiling followed by unbiased clustering and subsequent Xenium H&E alignment (see Methods). The MBM in the frontal lobe emerged under BRAFi/MEKi therapy and was resected ~5 weeks after treatment initiation. However, we observed activation of MAPK signal transduction as confirmed by phosphorylation of ERK1/2 (pERK1/2$^{Thr202/Tyr204}$) in both tumors, regardless of the treatment and rather governed by spatially-defined cues (Figure S17a, b).

Initial comparative spatial mapping and marker analysis of cell clusters revealed remarkable difference in the cellular composition of the matched, metachronous tumors particularly in the tumor cell fractions (TCs) and in the tumor microenvironmental (TME) cells (Figures 6b, c; S17c) which probably reflects the distinct cellular architecture of the cerebral and cerebellar cortexes which likely influenced tumor development. However, TargetSeq showed low genetic variability and maintenance of the proportion of BRAF^{V600E}-mutant cells (Figure S17d), which suggests an evolutionary connection between the tumors. The separated mapping of TCs and TMEs revealed obvious difference in the level of infiltration of immune (T) cells and TAMs (Figure 6b, c). Analysis of the 20 most highly expressed markers representing the major cell types revealed a prominent presence of TAMs, specified by 13 genes including CD68, C1QC, AIF1, and APOE, as well as immune cells, specified by the

expression of PTPRC, CD8A, CCL4, and CCL5 only in the frontal lobe tumor (Figure 6 d, e),

which is even more obvious when comparing the proportions of the most important cell types

(Figure 6f). Besides enrichment of immune cells and TAMs, we identified subsets showing

expression of inhibitors of insulin signaling IGFBP3 and IGFBP5, potential tumor

suppressors[59] and drivers[60] particularly in the frontal lobe MBM. Moreover, we found cycling

cells expressing TOP2A, PCNA, CENPF and MET as most persistent subsets[61,62] in both

tumors. As we assumed that the extent of immune cell infiltration was differentially regulated

in both tumors, we mapped SIRP and SIAP signatures. We found both programs expressed

and inversely correlated in the tumors, however SIAP was more evident in the frontal lobe

tumor as expected.

Since BZW2 and/or SOX4 act as potential suppressors of immune cell infiltration, they

determine SIRP and thus control disease progression by helping tumor cells evade immune

recognition. We performed an in-depth analysis of cellular subpopulations in SIAP^{high} areas

located in close proximity to vasculature-forming endothelial cells (Figure 6i) or at the

interface between tumor and TME cells (Figure 6j). As in other tumors, we observed that

immune (T) cells were predominantly localized in TAP1$^+$ areas, which in turn were embedded

in an immunosuppressive SOX4-expressing environment (Figure 6k, left panel). The

relationship between CD8A$^+$ cells and TAP1$^+$ tumor cells was even more evident in the

single-cell representation (Figure 6, right panel). TAP1$^+$ areas featuring high infiltration of T

cells and TAMs were primarily found in the frontal lobe tumor at the tumor-TME interface

(Figure 6l, left panel). Moreover, SIAP^{high} areas showed predominant enrichment of TAP1$^+$

and TRAC$^+$ T cells at the edge of the tumor at the transition to the microenvironment and

once more demonstrated the gradual decrease of infiltration into areas of

SOX4$^+$/MET$^+$/ABCB5$^+$ tumor cells. In summary, our data suggest that evolutionarily related

tumors can nevertheless form different ecosystems that exhibit varying degrees of immune

cell infiltration and thus may show a tumor-specific response to BRAFi/ICi.

Methods

Patient samples

All procedures performed in this study were in accordance with the ethical standards of the respective institutional research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients gave written informed consent for the collection and scientific use of tumor material which was collected at the Department of Neuropathology, Charité-Universitätsmedizin Berlin, Germany and Department of Pathology, Universitätsmedizin Greifswald, Greifswald, Germany. The usage of archived (FFPE) melanoma and central nervous system-derived control samples has been reviewed and approved by the Ethics Committee of the Charité (EA1/107/17 and EA1/075/19) and Universitätsmedizin Greifswald (BB 001/23).

Tissue microarray (TMA)

Hematoxylin and eosin (H&E)-stained brain metastasis tissue sections were examined to identify morphologically representative regions for inclusion in the tissue microarray (TMA) block. For each case, one to three tumor areas were selected under a conventional microscope (Nikon Eclipse Ni-U, Düsseldorf, Germany). Selected regions were marked on the slides and matched to the corresponding donor blocks. TMA construction was performed using a Manual Tissue Arrayer Model I (MTA-1; Estigen OÜ, Tartu, Estonia). A blank paraffin recipient block was first prepared, and cylindrical holes (1.5 mm diameter) were punched into it. Tissue cores of the same diameter were then extracted from the marked regions of the donor blocks and transferred into the recipient block, resulting in a TMA block containing 14 tissue cores (see graphical abstract, Figure 1). The completed TMA block was incubated at 60 °C for approximately 20 minutes to fuse the tissue cores with the paraffin. Finally, the block was sectioned and stained for downstream analysis.

DNA extraction and quantification

589   DNA was extracted from FFPE tissue using the Promega® RSC DNA FFPE Kit. Samples

590   were pretreated with 300 µL mineral oil at 80 °C for 2 minutes, followed by lysis with

591   proteinase K for 30 minutes at 56 °C. Extraction and quantification were performed

592   automatically using the Maxwell® RSC instrument (AS4500) and Quantus fluorometer

593   (QuantiFluor ONE dsDNA, Promega, USA).

Genetic Profiling of MBM using TruSight Oncology 500 (TSO500)

Library preparation followed the manufacturer's protocol (Illumina, USA). Briefly, 100 ng DNA

was sonicated using a Covaris ME220 sonicator (settings per Illumina, Table S1) to yield

fragments averaging 245 bp, confirmed via TapeStation 4150 (Agilent, USA). After end-

repair and A-tailing, adapters with unique molecular identifiers (UMIs) were ligated, followed

by index PCR. Target enrichment involved two hybridization steps with biotin-linked probes,

captured using streptavidin magnetic beads, and amplified by PCR. Libraries were bead-

normalized, pooled, denatured, diluted, and sequenced on an Illumina NextSeq 550 DX

(2×101 bp paired-end, dual index). Base call files (bcl) were processed using Illumina

DRAGEN TruSight Oncology 500 Analysis Software v2.5.3 for FASTQ generation, alignment

to hg19, variant calling, and QC evaluation (Q30, coverage >100×, contamination). All

metrics met Illumina specifications. Variants from DRAGEN were further annotated via

MyVariant.info's REST API, queried with the MyVariant Python module. Variants considered

included exonic SNVs, indels, splice mutations, and clinically relevant entries (ClinVar).

Polymorphisms were excluded based on the 1000 Genomes project, with a mutation allele

frequency threshold of 5%. Benign and likely benign variants were excluded from reporting.

Methylome profiling (EPICv2 Array)

For global methylome analysis, 100-250 ng genomic DNA were subjected to bisulfite

conversion using the EZ DNA Methylation-Gold Kit (Zymo Research) according to the

manufacturer's protocol. Subsequently, samples were analyzed on the Infinium

MethylationEPICv2 Kit (Illumina) according to the manufacturer's recommendations to obtain

genome-wide data from 950,000 CpG positions. Raw data from Illumina Epic arrays were

preprocessed and analyzed in the standard workflow of the packages RnBeads[63] and

watermelon[64] and CNV profiles were calculated using the conumee package[65].

Panel design

619   The panel was designed as previously described. Panel genes are shown Table S9.

Spatial transcriptomics analysis

Xenium in situ analysis (10X Genomics) was performed with the human brain base panel

(hBrain_v1, 266 genes) together with a 100 gene custom add-on panel. TMA and whole

tumor sections were prepared and processed according to manufacturer's guidelines

(CG000578, Rev D; CG000760, Rev A). Briefly, the sections underwent sequential

deparaffinization and permeabilization, followed by overnight hybridization with custom

probes at 50°C, rolling circle amplification, and slide-read out in the Xenium Analyzer. After

run completion, H&E staining were performed following Xenium guidelines (CG000613, B).

Processing and analysis of data

Spatial analysis of the Xenium readouts of TMA and MBM samples were analyzed using the

VoltRon (version 0.2.0) R package[30]. Individual TMA cores were interactively separated into

distinct samples using the *subset(object, interactive = TRUE)* function. TMA cores were

grouped into patient/donor of origin prior to downstream analysis. Cells with transcript counts

less than 5 were removed prior to clustering. Prior to clustering and cell type annotation, post

Xenium H&E images of TMA cores and remaining samples were automatically aligned to

DAPI channels of the Xenium data stored in the associated VoltRon objects using the

registerSpatialData function. Seurat (version 5) package[66] was used to perform downstream

unbiased clustering of Xenium cells from both TMA cores and the remaining MBM samples.

Log normalized counts (*NormalizeData* function) was performed with a scaling factor = 100.

This is followed by dimensionality reduction with PCA and UMAP, and then clustering with

shared nearest neighbor graphs (*FindNeighbors* and *FindClusters* function) using

parameters specific for each sample. UMAP of Xenium cells across all TMAs were calculated

using Harmony-based[67] integrated PCA embeddings of all TMAs. Marker analysis was

performed to detect differentially expressed (DE) genes specific to each cell cluster

(*FindAllMarkers* function). Cell types were annotated using a hybrid approach, specifically by

(i) investigating DE genes and **(ii)** interactively visualizing clustered cells and aligned H&E

images using TissUUmaps tool[68]. VoltRon objects were converted into anndata (h5ad) format

prior to interactive visualization using the *as.AnnData* function. We used the

AddModuleScore function from Seurat to calculate the immune module scores using a

predetermined set of genes. Cells associated with hot and cold regions, which are areas of

around the cells with high immune score were automatically detected via hot spot analysis

utilities available in VoltRon. We first constructed a spatial neighborhood graph to identify

pairs of cells within 40 or 50 pixel distances (*getSpatialNeighbors* function), and tested

significant local changes in the immune score for each cell using Getis-Ord[31] statistics. To

detect significant changes of gene expression across hot and cold regions we aggregated

the count of cells annotated as hot and cold, and then performed DE analysis with the

DESeq2 R package[69]. Aggregation was performed across (i) tumor cells and cells of the TME

or (ii) only tumor cells depending on the genes whose expression were compared across hot

and cold niches (Table S4).

Immunohistochemistry

Automated immunohistochemical staining of formalin-fixed, paraffin-embedded (FFPE) tissue

sections (2 μm thick) was performed on a VENTANA Benchmark XT automated staining

instrument (Ventana Medical Systems, Tucson, AZ) according to the manufacturer's

instructions. The primary and secondary antibodies used are listed in the Methods section.

Slides were deparaffinized using EZ Prep solution for 30 minutes at 75 °C. Antigen retrieval

was performed on the automated stainer using CC1 solution for 60 minutes at 95 °C. Primary

antibodies were then applied and visualized with either the iVIEW DAB Detection Kit or the

ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems). All

slides were counterstained with hematoxylin for 8 minutes. Immunohistochemical results

were independently evaluated by two consultants in neuropathology and pathology based on

predominant staining intensity. Omission of the primary antibodies, as a control for

nonspecific secondary antibody binding, resulted in absence of labeling. For validation,

positive control tissues - fixed and processed in the same manner as the test sections and

known to contain the target molecule (e.g., colon carcinoma) - were included in each staining

run.

MET-FISH analysis

MET-FISH for evaluation of MET amplification was performed as previously described[70].

678 Discussion

The tumor ecosystem is defined by the spatial interactions between the tumor and the

surrounding cells and is thought to change over time due to intrinsic factors such as

mutations or gene amplifications that drive subclonal evolution[71]. On the other hand, tissue-

resident cells such as cancer-associated fibroblasts (CAFs) or endothelial cells which

together with the extracellular matrix form the tumor bed. The ecosystem of brain metastases

comprises cells located specifically in the brain including astrocytes, oligodendrocytes,

microglia and neurons besides immune cells and macrophages which infiltrate the brain in

response to neuro-inflammatory processes[72]. Brain infiltrating tumor cells and neuro-

degenerative diseases such as Alzheimer and Stroke or Ischemia presents main

determinants of neuro-inflammation, mediated by activated astrocytes and microglia[73]. The

multitude of interactions between environmental cells in their ground state, i.e., in a non-

activated state, and tumor cells is in itself a complex process that probably defines the early

stages of asymptomatic brain metastasis. The complexity of this still not entirely understood

system increases in a time-depended manner, suggesting different types of ecosystems

(ground state/moderately inflamed and highly inflamed) which in turn distinctly respond to

therapeutic interactions.

Spatial transcriptomics-based profiling provided insights into the different stages of MBM

Our spatial transcriptomics approach provides for the first time insights into the spatial maps of MBM of different clinical stages, considering the NGFR[+] tumor stage representing a rather resistant, de-differentiated/ stem-like phenotype and the Ecad[+] subset of melanotic /pigmented MBM featuring therapy-naïve or responsive phenotypes. De-differentiation in general considerately forces tumor cell stemness and increasing tumor heterogeneity and drives immune evasion and resistance to immunotherapy[18,74], suggesting NGFR expression in melanoma as potential biomarker of ICi response. However, our approach revealed remarkable heterogeneity in the NGFR[+] cell fraction and suggests that factors e.g. reelin (RELN) potentially interacting with NGFR define the phenotypes of NGFR[+] tumor cells. Our approach confirmed coexisting and intermediate states and demonstrated the validity of our previously identified signature genes that classify Ecad/NGFR states. Although we found BZW2 and SOX4 among the most downregulated genes in BMCs with knockdown of NGFR, our spatial data suggest no direct regulatory association of NGFR and SOX4 or BZW2 but suggest a broader function in MBM. Bulk[19] and single-cell RNAseq MBM[75] studies revealed potential cellular subgroups but only the integration of spatial information revealed the distribution of immunologically cold, BZW2[+], and/or SOX4[+] and TAP1[+] areas with immune cell infiltration in the tumors. TAP1 serves as important antigen transporter in tumor cells and immune cells ensuring the presentation of antigens to T cells via MHC class I molecules. We initially observed this clear distinction between immune cell-enriched and depleted regions, which correlated with the expression of TAP1/BZW2, by spatial transcriptomics profiling and mapping to H&E of a primary mucosal melanoma. We found these regional differences in the associated MBM, suggesting that primarily the BZW2[+]/TAP1[low] tumor cells escaping immune surveillance are prone to metastasis or that immunosuppressive areas are re-established during the development of MBM, possibly in response to therapeutic interventions. On single cell-level we observed tumor cells with high abundance of either BZW2 or TAP1 transcripts as well as intermediate cells with moderate levels of both, however only the

BZW2[low]/TAP1[high] tumors were associated with favored survival of melanoma patients.

Moreover, we confirmed the relationship of BZW2 and TAP1 in additional tumor samples but

observed overlapping patterns of BZW2 and SOX4 acting in concert or in a substituting

manner.

Mechanistically, the direct regulation of NGFR and of the BZW2/AP1-axis in melanoma

remains elusive. SOX4 serves as a downstream target and mediator of epithelial-

mesenchymal transition (EMT) of TGFβ signaling in breast cancer[76] but this connection was

not particularly visible spatially. The competitive inhibitor of eukaryotic translation initiation

factor 5 (eIF5) BZW2 which represses translation starting at non-canonical start codons[77]

was potentially linked with mTOR signaling and associated with a pro-tumorigenic phenotype

in several cancers[78]. The regulation of TAP1 and of additional genes involved in the MHC

class I antigen-presentation pathway depends on interferon signaling[39,41,79] and on the key

transcriptional coactivator NLRC5[80] which is often silenced by promoter methylation[80].

However, additional studies will be required to uncover the regulation of immune suppressive

niches which can be defined not only by BZW2[+]. The automated profiling of "cold" and "hot"

niches using hot spot analysis, as predefined by the degree of immune cell infiltration

uncovered a spatial signature of markers of TAP1[+] niches. Niches comprised TAP1[+] tumor

cells and immune cells among other marker-defining cell types, particularly immune cells

(CCL4, ITGB2, LGALS9), TAMs (C1QC, FCER1G, AIF1) and niche forming tumor cells

(TAP1, HLA-DRA). For discrimination of immune "hot" and "cold" niches and calculation of

scores enabling the scoring of tumors, we defined gene signatures specifying the "spatial

immune activating program (SIAP)" or "spatial immune suppressive program (SIRP)". We

demonstrated that SIAP was predominantly expressed in tumors featuring a high immune

score and response to Ici therapy in contrast to SIRP expressing tumors.

A 10-gene IFNγ signature was identified that includes STAT1 and HLA-DRA among others

and predicts the response to ICi therapy[81]. In line, we observed "hot" niches associated with

IFN cells which showed high levels of mediators of interferon signaling such as MX1 or IFI6

and found STAT1 and HLA-DR(A) proteins expressed at sites of low BZW2/SOX4. Although

the circumstances of BZW2 regulation remains elusive, we assume that BZW2[+] cells exhibit

erroneous STAT1 expression and activation which in turn is responsible for low TAP1 levels

and impaired antigen presentation and immune (T) cell attraction.

In summary, we have identified a significant role for BZW2 and TAP1 as inversely correlated

tumor markers that correspond to a high or low degree of immune infiltration and spatially

separate tumors by yet undefined mechanisms. Therefore, the BZW2/TAP1 system could

serve as an additional level of immune regulation alongside the therapeutically important

PD1/PD-L1 axis.

Spatial profiling uncovered the cellular heterogeneity of tumors

Besides spatial mapping and characterization of immune niches, our approach provided

insights into the cellular composition of tumors and demonstrated an impressive

heterogeneity of tumor cellular subsets. We observed that progression was accompanied by

enrichment and depletion of cellular subsets, suggesting a restructuring of the tumor

ecosystem. The comparative spatial mapping, analysis of genetic and copy number profiles

uncovered MET receptor as a potential driver of brain metastatic progression. We found MET

receptor amplification in methylome-based CNV profiles of the mucosal melanoma-derived

MBM and loss of the driver mutation NRAS[Q61] as a potential sign of resistance and

progression[82]. Examination of the MET[+] cell fraction revealed at least five cellular subgroups

that co-expressed Ecad, ABCB5, BZW2, and SOX4 or showed MET

phosphorylation/activation. The large diversity of MET[+] subsets suggests that small molecule

MET inhibitors could eliminate immunosuppressive BZW2[+]/SOX4[+] subsets, making them a

promising second-line treatment strategy for BRAFi/ICi-resistant primary and (brain)

metastatic melanoma. As MET receptor serves as mediator of BRAFi resistance, the

combination of MET inhibitors potentially increase efficacy of ICi in BRAFi refractory tumors.

Besides MET, our survey allowed the sub-classification of the NGFR tumor cell fraction

which underscores that NGFR⁺ cells feature functional diversity depending on the co-

expressed and in concert acting genes.

The relevance of researching NGFR⁺ tumor cells in melanoma and other tumor types such

as glioblastoma has already been convincingly demonstrated by our own work and that of

other groups. We can therefore assume that there are several cellular and possibly

interconnected subgroups of, for example, MET and NGFR, which determine the

characteristics and response of tumors to therapies depending on the context. Spatial

transcriptomics paves the way for understanding the biology of these subgroups and their

therapeutic use.

Data Availability

A TissUUmaps-based interactive application of annotated Xenium cells and aligned post-

Xenium H&E images of all MBM samples are publicly available at

https://brain-melanoma-tissuumaps.mdc-berlin.de/ . All spatial transcriptomics raw data are

deposited at GEO (Gene Expression Omnibus; study GSE306955). For integrative analyses

our study included bulk expression data of MBM (study EGAS00001005975

(https://zenodo.org/record/7013097) and of melanoma prior and after ICi therapy (study by

Liu et al.) and single cell expression data of candidates BZW2, SOX4 and PD1/PD-L1 of

melanoma showing response or resistance to immune checkpoint inhibition (study

GSE115978); https://portals.broadinstitute.org/single_cell/study/melanoma-immunotherapy-

resistance) and therapy-naïve MBM (study GSE200218). For assessment of the potential

role of IGFBPs 3/5 in drug resistance, we investigated A375 cells with acquired resistance to

BRAFi/MEKi (study GSE164897).

Code Availability

The R scripts used to analyze TMA and MBM samples as well as scripts to generate the figures are available at https://github.com/LandthalerLab/MBM_Analysis_Manukyan.

Figure legends

Figure 1: Graphical abstract. We used Xenium 10X technology for single cell-resolved spatial transcriptome profiling of MBM (n=14), adjacent CNS samples (n=2) and primary CNS lymphoma (PCNSL, n=2) compiled in a TMA and whole MBM sections (n=4) (1, Sample preparation). Following processing and data analysis, molecular profiling unraveled molecular subtypes Ecad^{high}, NGFR^{high}/de-differentiated or the immune suppressive subgroups BZW2^{high} and/or SOX4^{high} (2, Subgroups). Our study uncovered TAP1 and BZW2/SOX4 as niche-determining factors and potential prognostic markers of melanoma survival (3, Immune resistance program).

Figure 2: BZW2 and TAP1 distinct spatially separated areas of immune cell infiltration.
a.) Left panel: UMAP representation of melanoma patients (n=14) showing high (red) or low (blue) level of resistance to immune checkpoint therapy (study GSE115978). Right panel: Levels of BZW2 expression in tumors shown in (a). The expression level is color coded. b.) Box plot representation of levels of BZW2 and SOX4 across single cells of pre-treatment tumors (n=1089 cells) and tumors with acquired resistance (n=792 cells). c.) Box plot representation of levels of BZW2 and SOX4 in samples shown in (a) featuring high or low levels of immune resistance. d.) Schematic summary of disease progression of Pat 90 who was first diagnosed with mucosal melanoma in the nasal cavity (09/2021). Lung metastases showed response to applied ICi (09/2022-02/2023). The emerged MBM was resected (06/2023), relapse was observed ~ 5 months later (11/2023). e.) Spatial visualization of areas of BZW2^{+} cells, proliferating BZW2^{+}/TOP2A^{+} cells, TAP1^{+} cells and immune cells as indicated by colors. f.) TargetSeq of primary mucosal melanoma (mM) and concordant brain

metastasis (mMBM) identified missense SNVs/MNVs (single/multiple nucleotide variants) or,

duplication (DUP), deletions (DEL) or insertions (INS); not detected (ND) or wildtype (wt) as

given by the color code. g.) Spatial representation of expression levels of BZW2 and TAP1 in

primary mM and mMBM showing discrete areas of BZW2$^+$ or TAP1$^+$ tumor cells upper,

center panels. Indicated H&E areas show immune-cell enriched areas (lower panels). h.)

Visualization of spatially-defined immune scores (ImmuneScores) in indicated tumors. i.)

Illustration of automatically detected (hot spot analysis) immunogenic "hot" (yellow) and

suppressive "cold" (blue) areas within a represented set of tumors. j.) Box plots showing

levels of selected representative markers for "hot" niches: TAP1, HLA-DRA, PD-L2

(PDCD1LG2) and ITGB2 (upper row) and "cold" niches: BZW2, PSENEN, SOX4 and SOX6

(lower row) as determined by DESeq2 analysis. All markers were significantly differentially

expressed between "hot" and "cold" areas across all aggregated niche-building tumor cells of

selected aggregated tumor samples (TMA and non-TMA). Box and whisker plots show

median (center line), the upper and lower quartiles (the box), and the range of the data (the

whiskers), including outliers. k.) reconstruction of an immunogenic niche, containing immune

(T) cells (pink) and TAMs (light pink) which are surrounded by TAP1$^+$ "hot" tumor cells (TCs,

greenish brown). The immunogenic niche in turn is embedded in the suppressive area by

BZW2$^+$ cells (blue) and intermediate cells (color gradient). Lower scheme: enlarged

illustration of cells indicated above indicting the distances of TAP1$^+$ and BZW2$^+$ cells to

nearest immune cells. l.) Violin plot indicating the distances of immunogenic and suppressive

tumor cells to nearest immune cells as calculated across n=61,071 TAP1$^+$ and n=146,947

BZW2$^+$ TCs. In b, c significance was determined by unpaired t-test, in (j) significance was

determined by DESeq2 analysis. m.) Transcript abundance and localization of TRAC, TAP1

and BZW2 (left panels) or CD8A, TAP1 and HLA-DRA (right panels) in single cells of

indicated (microscope symbols) sites of investigation of primary mM shown in (g). The

mutually exclusivity of BZW2 and TAP1 and association of TAP1 with HLA-DRA and CD8A is

shown. n.) Transcript abundance and localization of TRAC, TAP1 and BZW2 validating

distinct immune suppressive (BZW2$^+$) and T cell infiltrated (TRAC$^+$), immune supportive

(TAP1$^+$) areas. Endothelial cells are indicated by PECAM1.

Figure 3: Spatial and single cell profiling identified interferon signaling as a

component of immune cell-enriched niches. a.) Simplified scheme showing the principal

composition of immune cell-enriched niches. Tumor cells with high BZW2 levels surround

TAP1$^+$ cells, which in turn form the bed of immune cells. b.) Survival probability of melanoma

patients (TCGA-SKCM, n=459) featuring high or low levels of BZW2 and TAP1. Cox-

regression analysis revealed significant (Logrank P = 7.3x10^{-7}) dependence of overall

survival (OS) on BZW2 (HR=1.355) and TAP1 (HR=0.485). c.) Pattern of expression of

BZW2 and TAP1 in single (Malignant) tumor cells of therapy-naïve MBM (study

GSE200218). Expression is color coded. d.) Illustration of the top MBM expressed TAP1-

associated genes demonstrating enrichment of mediators of interferon (IFN) signaling

(STAt1, IFI6), immune proteasomes (PSMB8/9) and mediators of antigen transport and

presentation (HLAs A/C/E) and TAP2. e.) Box plot representation of expression levels of

MX1 and LGALS9 calculated across tumor cells and TME cells which represent the immune

cell enriched ("hot") niches. Significance was determined by a unpaired two-tailed, t-test. Box

and whisker plots show median (center line), the upper and lower quartiles (the box), and the

range of the data (the whiskers), including outliers. f.) Simplified scheme illustrating some

key players of interferon signaling, highlighting the most important IFN-regulated genes. g.-f.)

Spatial mapping of IFI6 (Interferon Alpha Inducible Protein 6) revealed hot spots in TAP1$^+$

areas in Pat90 mM and MBM (first panels). Characterization of major cell types within IFI6$^+$

primary and secondary immune niches unveiled T cells (TRAC$^+$) surrounded by TAP1$^+$/IFN$^+$

tumor cells (TCs). i.) Left panel: Composite illustration of STAT1$^+$ cells. Center panels: IHC of

Pat 90 tumors for STAT1. Right panel: Spatial neighborhood of MET$^+$ cells.

Figure 4: Spatial profiling uncovered distinct and common molecular subgroups

across multiple tumors. a.) Upper scheme: indicating the localization of TMA tumors (MBM,

PCNSL) and adjacent-normal CNS tissue at primary (nasal cavity, Pat 90) or intracranial

sites as indicated. Lower scheme: representation of proportions of major cell types indicating

the cellular heterogeneity of TMA samples. b.) UMAP of defined major cell types of TMA

samples revealed marker-based identification of tumor cell (TC) subsets and TME cells as

illustrated. c.) Heat map showing the top expressed markers of cellular, color coded subsets

shown in (b). d.) Spatial maps illustrating the expression of BZW2, SOX4, and NGFR in

tumor samples, sorted by immune score (IS). e.) UMAP representation of IS and expression

of BZW2 and TAP1, discriminating cellular subsets/tumor subtypes. The level of expression

is color coded. f.) Single cell spatial resolution of a TAP1[+] niche of an immune-depleted MBM

(Pat 23-P, punch C). g.) Abundance of transcripts of BZW2, TAP1, CD8A and CTLA4 (upper

panels) or TAP1, CD8A and HLA-DRA (lower panels) of the TAP1[+] niche shown in (f) h.)

Single cell spatial resolution of a TAP1[+] niche of Pat 90 mM, showing transcripts of TAP1

(red), CD8A (green), HLA-DRA (purple) and BZW2 (blue).

Figure 5: Spatial programs define progression stages. a.) Immunohistochemistry (IHC) of

a de-differentiated MBM (Pat 15) for BZW2 (brown) and CD3 (red). b.) Color coded immune

scores indicate the areas of high or low enrichment of immune cells. c.) Spatial landscapes

of punches from areas indicated in (a) showing marker-defined tumor cell subsets (TCs) and

environmental cells TAMs, immune cells, endothelial cells, vascular leptomeningeal cells

(VLMC)/cancer-associated fibroblasts (CAFs), astrocytes, oligodendrocytes and

uncharacterized cells as indicated. d.) Spatial mapping of SIRP and SIAP scores and CD8A

expression in punches characterized in (c). The expression level is color coded. e.) Spatial

mapping of SIRP (blue) and SIAP (red) in primary mucosal melanoma and the concordant

MBM (Pat 90). f.) Separation of defined immunogenic (hot) and suppressive (cold) areas by

expression of gene signatures indicating clinical benefit and favored prognosis: macrophages

in the TME or responses to ICi therapy (IMPRES, T-effector-interferon-γ-associated gene

expression, neoadjuvant response to anti-PD1 therapy; NRS, Nivolumab response) and

prognostic immune signatures (ESTIMATE, Roh) and SIRP and SIAP as assessed by

ssGSEA. g.) IHC of a progressive, NGFR[+], NRAS-mutated MBM indicating proteins levels of

TAP1 or BZW2 (brown) and CD3 (red), indicating close proximity (TAP1[+]) or distance

(BZW2) of Tumor cells and T cells. h.) Application of signatures shown in (f) and ssGSEA of

MBM (n=79, study EGAS00001003672) separating tumors regarding the level of infiltration of

tumor-infiltrating lymphocytes (TIL). i.) Left plot: t-SNE representation of single cell clustering

of melanoma (n=14 patients, study GSE115978) and levels and heterogeneity of immune

resistance (color coded). j.) Levels and heterogeneity of TAP1 expression (color coded) in

samples shown in (h). k.) Box plots showing expression levels of CDK1, LGALS3, STAT1

and IFI6 in ICI naïve (pre) or resistant (post) samples shown in (h). l.) Box plot showing

levels of BZW2 (expression of tumor bulk) in patients (n=62) who received ICi therapy and

progressed (PD, n=13) or achieved stable disease (SD, n=49) in line with RECIST

(Response Evaluation Criteria In Solid Tumors) criteria. m.) Single sample GSEA of

melanoma patients (n=71) who received ICi therapy (study GSE91961) and progressed (PD,

n=48) or achieved partial or complete response (PR/CR, n=23) for enrichment of SIRP, SIAP

or ImmuneScore signatures. n.) Box plot showing levels of SIRP and SIAP in non-responding

(PD) and responding (PR/CR) tumors. o.) First row: Box plots showing levels of PTPRZ1

and TRAC or CD8A and NRS in PD and PR/CR tumors (second row). p.) Box plot showing

the levels of BZW2 in breast cancer brain metastases (BCBM) and primary tumors. q.) Box

plot showing the level of SIAP in BCBM and primary tumors (left) and survival properties of

breast cancer patients with regards to level of BZW2 and TAP1 as indicated by line colors.

Figure 6: Spatial profiling revealed different ecosystems of concordant MBM from

different sites of the brain. a.) Schematic representation of the proposed seeding of

primary melanoma into the brain and the formation of metastases in the cerebellum and

frontal lobe. The derivation of the metastasis by seeding of the cerebellar metastasis is not

shown. The frontal lobe tumor which potentially emerged under BRAFi/MEKi therapy was

resected ~5 weeks after initiation of the therapy. b.) Spatial maps of the cerebellar tumor

indicating all cellular subsets, tumor cells (TCs) and cell of the tumor microenvironment

(TME) or only TCs or only TME cells. c.) Spatial maps of the frontal lobe tumor indicating

color coded cellular subsets as indicated in (b). d.-e.) Heat map representation of the top20

markers of the major cell types of the cerebellar or frontal lobe tumor. Most prominent

937 markers specifying immune cells or TAMs in the frontal lobe tumors are highlighted. f.)

938 Stacked bar plots showing the proportions of indicated major cell types of the cerebellar (CB)

939 or frontal lobe (FL) tumor. g.-h.) Spatial mapping of SIAP score levels and overlap of SIAP

940 (red) and SIRP (blue) in the cerebellar or frontal lobe tumor. i.-j.) Cellular representation of an

941 SIAP$^+$ area surrounding a vessel in the CB tumor or located at the tumor tissue-stroma

942 border in the FL tumor. The main cell types are color-coded as indicated. k.-l.) Left panel:

943 Representation of areas with TAP1-expressing niches that are embedded in

944 immunosuppressive SOX4$^+$ areas (k) or are enriched in T cells (CD8A) at the border with

945 stromal cells (DCN$^+$) (l). Right panels: Abundance of transcript of SOX4/ABCB5 in tumor cells

946 or TAP1 in tumor cells or co-expressed with TRAC/CD8A in T cells of a CB tumor niche

947 (upper panel) or abundance of transcripts of SOX4/MET/ABCB5 in tumor cells TAP1/TRAC

948 in T cells (lower panel). Gene-specifying transcripts are color coded.

950 **Figure S1: BZW2 and SOX4 serve as potent immune suppressors in MBM.** a.)

951 Intersection of genes expressed in MBM but not BC (n=530) and IRP (immune resistance

952 program, n=302) genes identified BZW2 and SOX4. b.) GSEA of bulk expression data from

953 MBM and BC samples for enrichment of IRP genes and genes characterizing the ICi-

954 responsive status in MBM with suppression of IRP. c.) Box plot representation of levels of

955 BZW2, SOX4 and CDK4 in brain controls (BC), MBM-derived cell lines (BMC) and MBM. d.)

956 UMAP representation of SOX4 expression in tumor cells of melanoma patients (n=14, study

957 GSE115978). The expression level is color coded. e.) Left panel: UMAP representation of

958 illustrating the PD1/PD-L1 status of patients in (d), center and right panels: Violin plots

959 indicating the expression levels of BZW2 and SOX4 in PD1^{pos}, PDL1^{pos} or PDL1^{neg} tumor

960 cells. f.) Box plot representation of levels of TAP1 and HLA-DRA across single cells of pre-

961 treatment tumors (n=1089 cells) and tumor with acquired resistance (n=792 cells). g.)

962 Survival probability of melanoma patients (TCGA-SKCM, n=459) featuring high or low levels

963 of BZW2 (left panel), SOX4 (center panel) and TAP1 (right panel). Cox-regression analysis

revealed significant (Logrank $P = 1.1 \times 10^{-3}$; $P = 1.9 \times 10^{-3}$; $P = 4.4 \times 10^{-6}$;) dependence of overall

survival (OS) on BZW2 (HR=1.550), SOX4 (HR=1.520) and TAP1 (HR=0.450). In b, d

significance was determined by a unpaired two-tailed, t-test. Box and whisker plots show

median (center line), the upper and lower quartiles (the box), and the range of the data (the

whiskers), including outliers.

Figure S2: Comparative spatial profiling revealed patterns of brain metastatic

progression. a.) Spatial mapping of disease progression of primary mucosal melanoma

(primary mM, initially diagnosed 09/21) to the brain (mMBM, resected 06/23) indicating

pronounced changed in the tumor ecosystems with particular focus on tumor cell subsets 4

(TCs_4, TAP1$^+$) and TCs_7/8 (SLC17A6$^+$). b.) Comparative UMAP indicating the enrichment,

depletion and overlapping of cellular subtypes which accompanied metastatic disease

progression. Cellular subsets are color coded. c.) Heat map representing the top expressed

markers in cellular subsets indicated in (a-b). Important cellular subsets are highlighted. d.)

Left panel: Proportions of indicated, color coded major cell types characterizing the indicated

tumors. Right panel: Stacked bar plot shows levels of BZW2 and TAP1 in indicated tumors.

e.) Comparative UMAPs indicating levels of BZW2 (first panel), TAP1 (center panel) and

SOX4 (right panel). The expression level is color coded.

Figure S3: Profiling revealed characteristics of immunogenic "hot" and suppressive

"cold" niches. a.) Single spatial mapping of BZW2 expression of immune scores (first and

second row) and composite visualization of BZW2 and immune scores (third row).

Automated detection and assignment of immune niches using hot spot analysis (fourth row)

and of niche-supporting "hot" tumor cells (fifth row). Expression levels and cellular subsets

are color coded. b.) Box plot representation of expression levels calculated across all niche-

encompassing tumor and TME cells of selected aggregated tumor samples (TMA and non-

TMA). Immune cell markers NKG7 (natural killer cells), CCL5, CD8A (both T cells), C1QC

(TAMs) were significantly enriched in "hot" niches. Levels of tumor cell markers MET and

IGFBP3 were calculated across all niche-building aggregated tumor cells. Box and whisker

plots show median (center line), the upper and lower quartiles (the box), and the range of the data (the whiskers), including outliers. In b significance was determined by significance was determined by DESeq2 analysis, corrected for multiple testing.

Figure S4: Methylome-based CNV analysis revealed amplification of MET receptor as potential driver of brain metastatic progression. a.) UMAP projection indicating the changes in immune scores (upper panel) and levels of CD8A expression (lower panel) in Pat 90 tumors (primary mM; MBM). Levels are color coded. b.) Illustration of chromosome-wide copy number changes, genes on chromosome (Chr.) 7, particularly MET are highlighted. c.) Upper panels: MET-FISH analysis of tumors shown in (a) revealed amplification of genes on chromosome 7 (CEN7 probe, red) such as MET (MET-specific probe, green). Lower panel: Box plots representing probe-specific counts of fluorescent signals of investigated DAPI-stained nuclei (n=50) in depicted tumor sample.

Figure S5: Levels of STAT1 and BZW2 determine survival of melanoma patients. a.) Survival probability of melanoma patients (TCGA-SKCM, n=459) featuring high or low levels of BZW2 (left panel) and HLA-DRA. Cox-regression analysis revealed significant (Logrank P = 6.1×10^{-9}) dependence of overall survival (OS) on BZW2 (HR=1.297) and HLA-DRA (HR=0.462). b.) Survival probability of melanoma patients with MBM (study EGAD00001005046, n=74) featuring high or low levels of TAP1. Cox-regression analysis revealed significant (Logrank P = 6.3×10^{-4}) dependence of overall survival (OS) on TAP1 (HR=0.420). c.) Malignant and non-malignant cells of therapy-naïve MBM (study GSE200218) are shown as indicated. d.) Survival probability of melanoma patients (TCGA-SKCM, n=459) featuring high or low levels of BZW2 (left panel) and STAT1. Cox-regression analysis revealed significant (Logrank P = 1.1×10^{-9}) dependence of overall survival (OS) on BZW2 (HR=1.403) and STAT1 (HR=0.449). e.) Spatial mapping of expression of SOX4 upper panels) and MET (lower panels) in primary mM and mMBM. f.) Composite representation of STAT1$^+$ cells in the immune cell niche. STAT1$^+$ cells were localized to TAP1$^+$ niches. g.) Spatial mapping of expression of STAT1 in primary mM and mMBM. f.)

Composite representation of STAT1$^+$ cells in the immune cell niche. STAT1$^+$ cells were localized to TAP1$^+$ niches. h.) Composite representation of SOX4$^+$ (upper panel) or PSENEN$^+$ (lower panel) cells in the immune cell niche. SOX4$^+$ and PSENEN$^+$ cells were localized to BZW2$^+$ immune "cold" areas in primary MBM.

Figure S6: Profiling of single TAP1^{high} and TAP1^{low} tumor cells revealed a TAP1-associated network. a.) Single cell resolved expression of MET, TAP1 and BZW2. The level of expression is color coded. b.) IHC for HLA-DRA indicating areas of presentation of neoantigens. c.) Network of the top30 identified TAP1-associated genes as analyzed by STRING.

Figure S7: UMAP-based clustering revealed prominent inter-tumor heterogeneity but homogeneity among replicate samples. a.) Table providing information about TMA specimen. b.) UMAP of the unintegrated Xenium cells across all TMAs, illustrating clustering of TMA samples which revealed common and unique cellular subsets. c.) UMAPs of Xenium cells split by individual TMA specimen as indicated by the color code.

Figure S8: Immunohistochemistry classified tumors into for Ecad$^+$ and NGFR$^+$ tumors. a.-b.) IHC for Ecad (red) and NGFR (brown) enabled sub classification of TMA tumor samples (a) and CNS tissue (b).

Figure S9: Immunohistochemistry for MLANA and HMB45 classified tumors into pigmented/differentiated and non-pigmented/de-differentiated. a.-b.) IHC for MART1/MLANA (a) and HMB45 (b) (indicated by brown staining) enabled sub classification of TMA tumor samples.

Figure S10: Immunohistochemistry for CD3 uncovered immunogenic niches. a.-b.) IHC for CD3 in TMA tumor specimen (a) CNS tissue (b) (indicated by brown staining) provided information about the degree of immune cell infiltration.

Figure S11: Spatial profiling and immunohistochemistry provided insights into inflammatory states of tumor-adjacent CNS tissue. a.-b.) IHC for Iba1/AIF1 in TMA tumor

specimen (a) (indicated by brown staining) provided information about the degree of infiltration of tumor-associated macrophages/microglia (TAMs).

Figure S12: Profiling of immune cell niches revealed concomitant IFN signaling. a.) UMAP visualization illustrates the clustering of TMA samples according to donor characteristics. b.) Spatial maps illustrating the expression of MET, ABCB5, and Ecad in samples. c.-e.) UMAP representation of expression of HLA-DRA (c), MET (d) and SOX4 (e), discriminating cellular subsets/tumor subtypes. f.) Investigation of the spatial pattern of expression of BZW2, SOX4, TAP1 (first row) or HLA-DRA, ISG15 and immune scores (second row) or IFI6, IFI44L, PTPRC (third row) or MX2, MX1, CD8A (fourth row) of an immune cell niche in Pat23-P (punch C). g.) Cellular deconvolution and investigation of the spatial pattern of expression of TAP1 (first row), immune scores, BZW2 (second row) or PTPRC, SOX4 (third row) or IFI6, CD8A (fourth row). In (c.-g.) the level of expression is color coded.

Figure S13: Single cell profiling uncovered cellular heterogeneity of immune and tumor cells of immunogenic niches. a.) Abundance of transcripts of BZW2, TAP1, CD8A and HLA-DRA in single cells of an immune niche in Pat90 (primary mM) indicating co-expression of TAP1 and HLA-DRA in tumor cells and in CD8A$^+$ T cells.

Figure S14: Single cell profiling uncovered reactive states of tumor-adjacent astrocytes. a.) H&E staining (upper row) and Iba1/AIF1 of CNS normal_1 indicating areas of TAM activation in distant and adjacent areas of the tumor. b.) Spatial distinct patterns of GFAP expression (first column) in tumor-adjacent, reactive astrocytes (second column) and astrocytes at distant areas (third column). c.) UMAP presentation of major cell types of CNS tissue (a) indicating cellular subsets and different states of astrocytes. d.) UMAP presentation of expression levels of GFAP, CHI3L1, GJA1 (upper row) or MOG, SNAP25, SPP1 (lower row). e.) Spatial representation of cellular subsets in (a) showing enrichment and clear separation of areas of homeostatic (hom.) and reactive (react.) astrocytes and localization of neurons at particularly tumor-distant areas. f.) Spatial representation of expression levels of

GFAP, CHI3L1, GJA1 (upper row) or MOG, SNAP25, SPP1 (lower row). g.) Composite

presentation of reactive astrocytes (CHI3L1$^+$), neurons (SNAP25$^+$) and oligodendrocytes

(MOG$^+$), (left map) or reactive TAMs (AIF1+), neurons (SNAP25$^+$) and oligodendrocytes

(MOG$^+$) (right map). h.) Bubble plot indicating the top expressed markers in cellular subsets

of (a). In c, h, cellular subsets are color coded; in d, f, expression levels are color coded.

Figure S15: BZW2 and SOX4 classify cellular subgroups of MET expressing tumor

cells. a.) UMAP-based representation of cellular subsets of Pat 90 (mMBM) indicating tumor

cell heterogeneity (TCs) and TME cells. b.) UMAP-based representation of expression levels

of MET, Ecad/CDH1, ABCB5 (upper row) or SOX4, BZW2, TAP1 (lower row). c.) Spatial

representation of cellular subsets of Pat 90 (mMBM) indicating tumor cell heterogeneity

(TCs) and TME cells. d.) Spatial representation of expression levels of MET, Ecad/CDH1,

ABCB5 (upper row) or SOX4, BZW2, TAP1 (lower row). e.) Abundance of transcripts of MET,

ABCB5, SOX4, BZW2 in single cells (first column) and IHC of pMET and Ecad (second

column) indicating tumor cell subsets defined by expression of SOX4 and activation of MET.

f.) Heat map showing expression of top markers of cellular subsets. g.-i.) Survival probability

of melanoma patients (TCGA-SKCM, n=459) featuring high or low levels of MET and BZW2

(left panel), MET and SOX4 (center panel) or BZW2 and SOX4. Cox-regression analysis

revealed significant (Logrank P = 6.6×10^{-4}) dependence of overall survival (OS) on MET

(HR=1.412) and BZW2 (HR=1.542) and dependence of overall survival on MET (HR=1.372)

and SOX4 (HR=1.480), Logrank P = 7.5×10^{-4} and dependence of overall survival on BZW2

(HR=1.435) and SOX4 (HR=1.404), Logrank P = 5.1×10^{-4}.

Figure S16: Single cell spatial profiling uncovered cellular subsets of NGFR$^+$ MBM. a.)

UMAP-based representation of cellular subsets of Pat 23-P (MBM) indicating tumor cell

heterogeneity (TCs) and TME cells. b.) UMAP-based representation of expression levels of

NGFR, TRIL, AXL (upper row) or LIFR, TOP2A, LOX (lower row). c.) Spatial representation

of cellular subsets of Pat 23-P (MBM) indicating tumor cell heterogeneity (TCs) and TME

cells. d.) Spatial representation of expression levels of NGFR, TRIL, AXL (upper row) or

LIFR, TOP2A, LOX (lower row). e.) Abundance of transcripts of NGFR, APP in single cells

(first column) and IHC of NGFR and APP (second column) indicating tumor cell subsets

which are defined by APP-mediated activation of NGFR. f.) Heat map showing expression of

top markers of cellular subsets, selected tumor cell subsets are highlighted. g.-i.) Survival

probability of melanoma patients (TCGA-SKCM, n=459) featuring high or low levels of NGFR

and SOX4 (left panel), NGFR and APP (center panel) or NGFR and AXL. Cox-regression

analysis revealed significant (Logrank $P = 1.6 \times 10^{-3}$) dependence of overall survival (OS) on

NGFR (HR=1.412) and SOX4 (HR=1.542) and dependence of overall survival on NGFR

(HR=0.657) and APP (HR=0.790), Logrank $P = 5.1 \times 10^{-3}$ and dependence of overall survival

on NGFR (HR=0.769) and AXL (HR=0.560), Logrank $P = 5.4 \times 10^{-6}$.

Figure S17: The distinct ecosystems of concordant MBM. a.) Analysis of concordant,

metachronous MBM: IHC for phosphorylated and activated ERK1/2 kinase

(pERK1/2$^{Thr202/Tyr204}$) indicating focused areas of activation in the pre-relapse tumor and

restored activation in the post relapse tumor. Entire tumor sections (first column), tumor

areas which have been selected for spatial transcriptomics investigation and (second

column, red dashed line) and magnified areas of ERK activation in pre- and resistant/post-

relapse tumors. b.) IHC of TMA samples concordant to punched areas as indicated in entire

sections. c.) UMAP presentation of cellular subsets in post-relapse and pre-relapse tumors

indicating pronounced compositional changes in cellular subfractions. d.) TargetSeq of

primary (pre) and resistant/relapsed (post) MBM identified missense SNVs/MNVs

(single/multiple nucleotide variants) or, duplication (DUP), deletions (DEL) or insertions

(INS); frameshift variants, inframe deletions, splice donor variants or 3´-UTR variants not

detected (ND) or wildtype (wt) as given by the color code.

1121

1122

1123   **Acknowledgements**

We would like to thank all collaborators, technical staff, and laboratory personnel who contributed to this study. We are especially grateful to Michele Peters, Ayad W.H. Dawood, Andreas Wendt, Dana Ristau, Katrin Müller, Tanja Propp, Betty Nedow, Jenny Hagemann, and Diana Krüger for their support with sample preparation, immunohistochemistry, sequencing, analysis, and technical assistance. This work was supported by the German Federal Ministry of Education and Research (BMBF): NATON, No. 01KX2121 to H.R. and Seed funding from University Medicine Greifswald to K.P. and by the European Regional Development Fund (EFRE) (Target-H; FV-2024-0022) to JR.

Author Contributions

AM, KP, JR, and TR conceived and designed the study, performed experiments, collected data, analyzed the data, and drafted the manuscript. EW, HR, TC, JA, IP, AA, FR, AL, KK, KJ, and ML performed experiments and provided essential resources. EW contributed substantially to the conceptual development and critical revision of the manuscript. All authors critically revised the manuscript for intellectual content and approved the final version for submission.

References

1   Thomas, F. *et al.* A new perspective on tumor progression: Evolution via selection for function. *Evol Med Public Health* **12**, 172–177 (2024). https://doi.org/10.1093/emph/eoae021

2   Huang, S. Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. *Cancer Metastasis Rev* **32**, 423–448 (2013). https://doi.org/10.1007/s10555-013-9435-7

3   Vogelstein, B. *et al.* Cancer genome landscapes. *Science* **339**, 1546–1558 (2013). https://doi.org/10.1126/science.1235122

4   Brastianos, P. K. *et al.* Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discov* **5**, 1164–1177 (2015). https://doi.org/10.1158/2159-8290.CD-15-0369

5   Rigg, E. *et al.* Inhibition of extracellular vesicle-derived miR-146a-5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes. *J Extracell Vesicles* **12**, e12363 (2023). https://doi.org/10.1002/jev2.12363

6   Schroeder, T. *et al.* Mapping distribution of brain metastases: does the primary tumor matter?
J Neurooncol **147**, 229–235 (2020). https://doi.org/10.1007/s11060-020-03419-6
7   Redmer, T. Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter.
Mol Cancer **17**, 106 (2018). https://doi.org/10.1186/s12943-018-0854-5
8   Lau, P. K. H. *et al.* Melanoma brain metastases that progress on BRAF-MEK inhibitors
demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1
Resistance Signature (IPRES). *J Immunother Cancer* **9** (2021). https://doi.org/10.1136/jitc-
2021-002995
9   Serra, E. *et al.* Predictive and Prognostic Factors in Melanoma Central Nervous System
Metastases—A Cohort Study. *Cancers* **16**, 2272 (2024).
10   Winkler, F. The brain metastatic niche. *Journal of Molecular Medicine* **93**, 1213–1220 (2015).
https://doi.org/10.1007/s00109-015-1357-0
11   Wen, J., Li, Y., Deng, W. & Li, Z. Central nervous system and immune cells interactions in
cancer: unveiling new therapeutic avenues. *Frontiers in Immunology* **Volume 16 - 2025**
(2025). https://doi.org/10.3389/fimmu.2025.1528363
12   Lin, X. *et al.* Regulatory mechanisms of PD-1/PD-L1 in cancers. *Molecular cancer* **23**, 108
(2024). https://doi.org/10.1186/s12943-024-02023-w
13   Jerby-Arnon, L. *et al.* A Cancer Cell Program Promotes T Cell Exclusion and Resistance to
Checkpoint   Blockade.   *Cell*   **175**,   984–997.e924   (2018).
https://doi.org/10.1016/j.cell.2018.09.006
14   Tawbi, H. A. *et al.* Long-term outcomes of patients with active melanoma brain metastases
treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-
label,   multicentre,   phase   2   study.   *Lancet   Oncol*   **22**,   1692–1704   (2021).
https://doi.org/10.1016/s1470-2045(21)00545-3
15   Liu, T., Zhou, L., Xiao, Y., Andl, T. & Zhang, Y. BRAF Inhibitors Reprogram Cancer-
Associated Fibroblasts to Drive Matrix Remodeling and Therapeutic Escape in Melanoma.
Cancer research **82**, 419–432 (2022). https://doi.org/10.1158/0008-5472.Can-21-0614
16   Auslander, N. *et al.* Robust prediction of response to immune checkpoint blockade therapy in
metastatic melanoma. *Nat Med* **24**, 1545–1549 (2018). https://doi.org/10.1038/s41591-018-
0157-9
17   Huang, A. C. *et al.* A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in
resectable melanoma. *Nat Med* **25**, 454–461 (2019). https://doi.org/10.1038/s41591-019-
0357-y
18   Boshuizen, J. *et al.* Reversal of pre-existing NGFR-driven tumor and immune therapy
resistance. *Nat Commun* **11**, 3946 (2020). https://doi.org/10.1038/s41467-020-17739-8
19   Radke, J. *et al.* Decoding molecular programs in melanoma brain metastases. *Nature
Communications* **13**, 7304 (2022). https://doi.org/10.1038/s41467-022-34899-x
20   In, G. K. *et al.* Multi-omic profiling reveals discrepant immunogenic properties and a unique
tumor microenvironment among melanoma brain metastases. *NPJ Precis Oncol* **7**, 120
(2023). https://doi.org/10.1038/s41698-023-00471-z
21   Kluger, H. M. *et al.* Characterization of PD-L1 Expression and Associated T-cell Infiltrates in
Metastatic Melanoma Samples from Variable Anatomic Sites. *Clinical Cancer Research* **21**,
3052–3060 (2015). https://doi.org/10.1158/1078-0432.Ccr-14-3073
22   Kleffel, S. *et al.* Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Cell **162**, 1242–1256 (2015). https://doi.org/10.1016/j.cell.2015.08.052
23   Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor
microenvironment. *Science* **348**, 74–80 (2015). https://doi.org/10.1126/science.aaa6204
24   Handel, E. E. *et al.* Outcomes following long-term disease control with immune checkpoint
inhibitors in patients with advanced melanoma. *European journal of cancer* **215**, 115171
(2025). https://doi.org/https://doi.org/10.1016/j.ejca.2024.115171
25   Margolin, K. *et al.* Ipilimumab in patients with melanoma and brain metastases: an open-label,
phase   2   trial.   *Lancet   Oncol*   **13**,   459–465   (2012).   https://doi.org/10.1016/S1470-
2045(12)70090-6
26   Singh, C. R. *et al.* Mechanisms of translational regulation by a human eIF5-mimic protein.
Nucleic Acids Res **39**, 8314–8328 (2011). https://doi.org/10.1093/nar/gkr339
27   Zawerton, A. *et al.* De Novo SOX4 Variants Cause a Neurodevelopmental Disease Associated
with   Mild   Dysmorphism.   *Am   J   Hum   Genet*   **104**,   246–259   (2019).
https://doi.org/10.1016/j.ajhg.2018.12.014
28   Ritz, U. & Seliger, B. The Transporter Associated With Antigen Processing (TAP): Structural
Integrity, Expression, Function, and Its Clinical Relevance. *Molecular Medicine* **7**, 149–158
(2001). https://doi.org/10.1007/BF03401948

29   Yoshihara, K. *et al.* Inferring tumour purity and stromal and immune cell admixture from
expression data. *Nat Commun* **4**, 2612 (2013). https://doi.org/10.1038/ncomms3612
30   Manukyan, A. *et al.* VoltRon: A Spatial Omics Analysis Platform for Multi-Resolution and Multi-
omics Integration using Image Registration. *bioRxiv*, 2023.2012.2015.571667 (2023).
https://doi.org/10.1101/2023.12.15.571667
31   Getis, A. & Ord, J. K. The Analysis of Spatial Association by Use of Distance Statistics.
Geographical Analysis **24**, 189–206 (1992). https://doi.org/https://doi.org/10.1111/j.1538-
4632.1992.tb00261.x
32   Hugo, W. *et al.* Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in
Metastatic Melanoma. *Cell* **168**, 542 (2017). https://doi.org/10.1016/j.cell.2017.01.010
33   Heng, Y. *et al.* High Expression of Tumor HLA-DR Predicts Better Prognosis and Response to
Anti-PD-1 Therapy in Laryngeal Squamous Cell Carcinoma. *Translational Oncology* **33**,
101678 (2023). https://doi.org/https://doi.org/10.1016/j.tranon.2023.101678
34   Tabassum, A. *et al.* Transporter associated with antigen processing 1 (TAP1) expression and
prognostic analysis in breast, lung, liver, and ovarian cancer. *J Mol Med (Berl)* **99**, 1293–1309
(2021). https://doi.org/10.1007/s00109-021-02088-w
35   Holling, T. M., van der Stoep, N., Quinten, E. & van den Elsen, P. J. Activated Human T Cells
Accomplish MHC Class II Expression Through T Cell-Specific Occupation of Class II
Transactivator Promoter III1. *The Journal of Immunology* **168**, 763–770 (2002).
https://doi.org/10.4049/jimmunol.168.2.763
36   Van Kaer, L., Ashton-Rickardt, P. G., Ploegh, H. L. & Tonegawa, S. TAP1 mutant mice are
deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. *Cell* **71**,
1205–1214 (1992). https://doi.org/10.1016/s0092-8674(05)80068-6
37   Ling, A. *et al.* TAP1 down-regulation elicits immune escape and poor prognosis in colorectal
cancer. *Oncoimmunology* **6**, e1356143 (2017).
https://doi.org/10.1080/2162402x.2017.1356143
38   Dhatchinamoorthy, K., Colbert, J. D. & Rock, K. L. Cancer Immune Evasion Through Loss of
MHC Class I Antigen Presentation. *Front Immunol* **12**, 636568 (2021).
https://doi.org/10.3389/fimmu.2021.636568
39   Min, W., Pober, J. S. & Johnson, D. R. Kinetically coordinated induction of TAP1 and HLA
class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha.
J Immunol **156**, 3174–3183 (1996).
40   Kanatani, S. *et al.* Whole-brain spatial transcriptional analysis at cellular resolution. *Science*
386, 907–915 (2024). https://doi.org/doi:10.1126/science.adn9947
41   Heise, R. *et al.* Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of
Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant
Melanoma. *PloS one* **11**, e0146325 (2016). https://doi.org/10.1371/journal.pone.0146325
42   Cramer, L. A., Nelson, S. L. & Klemsz, M. J. Synergistic induction of the Tap-1 gene by IFN-
gamma and lipopolysaccharide in macrophages is regulated by STAT1. *J Immunol* **165**,
3190–3197 (2000). https://doi.org/10.4049/jimmunol.165.6.3190
43   Luskin, M. R., Murakami, M. A., Manalis, S. R. & Weinstock, D. M. Targeting minimal residual
disease: a path to cure? *Nat Rev Cancer* **18**, 255–263 (2018).
https://doi.org/10.1038/nrc.2017.125
44   Rambow, F. *et al.* Toward Minimal Residual Disease-Directed Therapy in Melanoma. *Cell* **174**,
843–855 e819 (2018). https://doi.org/10.1016/j.cell.2018.06.025
45   Lehmann, J. *et al.* Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling
in melanoma. *Sci Adv* **9**, eadc8825 (2023). https://doi.org/10.1126/sciadv.adc8825
46   Busselaar, J., Sijbranda, M. & Borst, J. The importance of type I interferon in orchestrating the
cytotoxic T-cell response to cancer. *Immunology Letters* **270**, 106938 (2024).
https://doi.org/https://doi.org/10.1016/j.imlet.2024.106938
47   Nguyen, T. H. *et al.* Frequency of HLA-DR[+]CD38[hi] T cells identifies
and quantifies T-cell activation in hemophagocytic lymphohistiocytosis, hyperinflammation,
and immune regulatory disorders. *Journal of Allergy and Clinical Immunology* **153**, 309–319
(2024). https://doi.org/10.1016/j.jaci.2023.07.008
48   Prinz, M., Jung, S. & Priller, J. Microglia Biology: One Century of Evolving Concepts. *Cell* **179**,
292–311 (2019). https://doi.org/10.1016/j.cell.2019.08.053
49   Doron, H., Pukrop, T. & Erez, N. A Blazing Landscape: Neuroinflammation Shapes Brain
Metastasis. *Cancer Res* **79**, 423–436 (2019). https://doi.org/10.1158/0008-5472.Can-18-1805
50   Henrik Heiland, D. *et al.* Tumor-associated reactive astrocytes aid the evolution of
immunosuppressive environment in glioblastoma. *Nature Communications* **10**, 2541 (2019).
https://doi.org/10.1038/s41467-019-10493-6

| 1278 | 51 | Zamanian, J. L. *et al.* Genomic Analysis of Reactive Astrogliosis. *The Journal of Neuroscience* |
| 1279 | | **32**, 6391–6410 (2012). https://doi.org/10.1523/jneurosci.6221-11.2012 |

51 Zamanian, J. L. *et al.* Genomic Analysis of Reactive Astrogliosis. *The Journal of Neuroscience*
32, 6391–6410 (2012). https://doi.org/10.1523/jneurosci.6221-11.2012
52 Lawrence, J. M., Schardien, K., Wigdahl, B. & Nonnemacher, M. R. Roles of neuropathology-
associated reactive astrocytes: a systematic review. *Acta Neuropathologica Communications*
11, 42 (2023). https://doi.org/10.1186/s40478-023-01526-9
53 Jurga, A. M., Paleczna, M., Kadluczka, J. & Kuter, K. Z. Beyond the GFAP-Astrocyte Protein
Markers in the Brain. *Biomolecules* **11** (2021). https://doi.org/10.3390/biom11091361
54 Sofroniew, M. V. Astrocyte Reactivity: Subtypes, States, and Functions in CNS Innate
Immunity. *Trends Immunol* **41**, 758–770 (2020). https://doi.org/10.1016/j.it.2020.07.004
55 Landsberg, J. *et al.* Melanomas resist T-cell therapy through inflammation-induced reversible
dedifferentiation. *Nature* **490**, 412–416 (2012). https://doi.org/10.1038/nature11538
56 Roukens, M. G. *et al.* Regulation of a progenitor gene program by SOX4 is essential for
mammary tumor proliferation. *Oncogene* **40**, 6343–6353 (2021).
https://doi.org/10.1038/s41388-021-02004-z
57 Liu, Y. *et al.* A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune
surveillance to drive breast cancer progression. *Developmental cell* **58**, 2700–2717.e2712
(2023). https://doi.org/10.1016/j.devcel.2023.10.010
58 Tsang, S. M., Oliemuller, E. & Howard, B. A. Regulatory roles for SOX11 in development,
stem cells and cancer. *Seminars in cancer biology* **67**, 3–11 (2020).
https://doi.org/https://doi.org/10.1016/j.semcancer.2020.06.015
59 Panasiti, V. *et al.* Correlation between insulin-like growth factor binding protein-3 serum level
and melanoma progression. *Journal of the American Academy of Dermatology* **64**, 865–872
(2011). https://doi.org/https://doi.org/10.1016/j.jaad.2010.03.035
60 Becker, M. A. *et al.* IGFBP ratio confers resistance to IGF targeting and correlates with
increased invasion and poor outcome in breast tumors. *Clin Cancer Res* **18**, 1808–1817
(2012). https://doi.org/10.1158/1078-0432.Ccr-11-1806
61 Yu, B. *et al.* TOP2A and CENPF are synergistic master regulators activated in cervical cancer.
BMC Medical Genomics **13**, 145 (2020). https://doi.org/10.1186/s12920-020-00800-2
62 Zhao, H. C. *et al.* CD168(+) macrophages promote hepatocellular carcinoma tumor stemness
and progression through TOP2A/β-catenin/YAP1 axis. *iScience* **26**, 106862 (2023).
https://doi.org/10.1016/j.isci.2023.106862
63 Muller, F. *et al.* RnBeads 2.0: comprehensive analysis of DNA methylation data. *Genome Biol*
20, 55 (2019). https://doi.org/10.1186/s13059-019-1664-9
64 Pidsley, R. *et al.* A data-driven approach to preprocessing Illumina 450K methylation array
data. *BMC Genomics* **14**, 293 (2013). https://doi.org/10.1186/1471-2164-14-293
65 Daenekas, B. *et al.* Conumee 2.0: enhanced copy-number variation analysis from DNA
methylation arrays for humans and mice. *Bioinformatics* **40** (2024).
https://doi.org/10.1093/bioinformatics/btae029
66 Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 e3529
(2021). https://doi.org/10.1016/j.cell.2021.04.048
67 Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony.
Nature methods **16**, 1289–1296 (2019). https://doi.org/10.1038/s41592-019-0619-0
68 Pielawski, N. *et al.* TissUUmaps 3: Improvements in interactive visualization, exploration, and
quality assessment of large-scale spatial omics data. *Heliyon* **9**, e15306 (2023).
https://doi.org/https://doi.org/10.1016/j.heliyon.2023.e15306
69 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014). https://doi.org/10.1186/s13059-
014-0550-8
70 Redmer, T. *et al.* MET receptor serves as a promising target in melanoma brain metastases.
Acta Neuropathol **147**, 44 (2024). https://doi.org/10.1007/s00401-024-02694-1
71 de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to
metastatic outgrowth. *Cancer cell* **41**, 374–403 (2023).
https://doi.org/10.1016/j.ccell.2023.02.016
72 Passaro, A. P., Lebos, A. L., Yao, Y. & Stice, S. L. Immune Response in Neurological
Pathology: Emerging Role of Central and Peripheral Immune Crosstalk. *Front Immunol* **12**,
676621 (2021). https://doi.org/10.3389/fimmu.2021.676621
73 Sofroniew, M. V. Molecular dissection of reactive astrogliosis and glial scar formation. *Trends*
Neurosci **32**, 638–647 (2009). https://doi.org/10.1016/j.tins.2009.08.002
74 Li, J. & Stanger, B. Z. How Tumor Cell Dedifferentiation Drives Immune Evasion and
Resistance to Immunotherapy. *Cancer Res* **80**, 4037–4041 (2020).
https://doi.org/10.1158/0008-5472.Can-20-1420

1339 75 Biermann, J. *et al.* Dissecting the treatment-naive ecosystem of human melanoma brain
1340   metastasis. *Cell* **185**, 2591–2608 e2530 (2022). https://doi.org/10.1016/j.cell.2022.06.007
1341 76 Vervoort, S. J., Lourenço, A. R., van Boxtel, R. & Coffer, P. J. SOX4 Mediates TGF-β-Induced
1342   Expression of Mesenchymal Markers during Mammary Cell Epithelial to Mesenchymal
1343   Transition. *PloS one* **8**, e53238 (2013). https://doi.org/10.1371/journal.pone.0053238
1344 77 Andreev, D. E. *et al.* Non-AUG translation initiation in mammals. *Genome Biol* **23**, 111 (2022).
1345   https://doi.org/10.1186/s13059-022-02674-2
1346 78 Li, C., Li, Q., Li, L., Sun, S. & Lei, X. The Prognostic and Immune Significance of BZW2 in
1347   Pan-Cancer and its Relationship with Proliferation and Apoptosis of Cervical Cancer. *FBL* **29**
1348   (2024). https://doi.org/10.31083/j.fbl2903097
1349 79 Garcia-Diaz, A. *et al.* Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2
1350   Expression. *Cell reports* **19**, 1189–1201 (2017).
1351   https://doi.org/https://doi.org/10.1016/j.celrep.2017.04.031
1352 80 Yoshihama, S., Vijayan, S., Sidiq, T. & Kobayashi, K. S. NLRC5/CITA: A Key Player in Cancer
1353   Immune Surveillance. *Trends Cancer* **3**, 28–38 (2017).
1354   https://doi.org/https://doi.org/10.1016/j.trecan.2016.12.003
1355 81 Ayers, M. *et al.* IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. *The*
1356   *Journal of clinical investigation* **127**, 2930–2940 (2017). https://doi.org/10.1172/JCI91190
1357 82 Niknafs, N. *et al.* Persistent mutation burden drives sustained anti-tumor immune responses.
1358   *Nat Med* **29**, 440–449 (2023). https://doi.org/10.1038/s41591-022-02163-w

1359

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6